<?xml version="1.0" encoding="UTF-8"?>

<Bundle xmlns="http://hl7.org/fhir">
  <id value="37144"/>
  <meta>
    <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
  </meta>
  <language value="da"/>
  <identifier>
    <system value="https://www.indlaegssedler.dk/Indlaegssedler/Indlaegsseddel/"/>
    <value value="37144"/>
  </identifier>
  <type value="document"/>
  <timestamp value="2021-07-20T01:01:01Z"/>
  <entry>
    <fullUrl value="https://gravitatehealth.eu/fhir/nordic-epi/Composition/37144"/>
    <resource>
      <Composition>
        <id value="37144"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
          <profile value="https://gravitatehealth.eu/fhir/nordic-epi-ig/StructureDefinition/Nordic-ePI-Composition-PIL"/>
        </meta>
        <language value="da"/>
        <text>
          <status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml" xml:lang="da" lang="da"><a name="Composition_37144"> </a><p><b>Generated Narrative: Composition</b><a name="37144"> </a><a name="hc37144"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Resource Composition &quot;37144&quot;  (Language &quot;da&quot;) </p><p style="margin-bottom: 0px">Profiles: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info//StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a>, <code>https://gravitatehealth.eu/fhir/nordic-epi-ig/StructureDefinition/Nordic-ePI-Composition-PIL</code></p></div><p><b>identifier</b>: <code>https://www.indlaegssedler.dk/Indlaegssedler/Indlaegsseddel/</code>/37144</p><p><b>status</b>: final</p><p><b>type</b>: 100000155538 <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#100000155538)</span></p><p><b>date</b>: 2021-07-20</p><p><b>author</b>: <span><code>https://medicin.dk</code>/medicin.dk</span></p><p><b>title</b>: Hyrimoz 40 mg injektionsv√¶ske, opl. i pen</p><hr/><blockquote><p><b>Generated Narrative: Binary #175114</b><a name="175114"> </a><a name="hc175114"> </a></p><p><b>contentType</b>: image/jpg</p><p><b>data</b>: (base64 data - 23143 bytes)</p></blockquote><hr/><blockquote><p><b>Generated Narrative: Binary #175115</b><a name="175115"> </a><a name="hc175115"> </a></p><p><b>contentType</b>: image/jpg</p><p><b>data</b>: (base64 data - 14678 bytes)</p></blockquote><hr/><blockquote><p><b>Generated Narrative: Binary #175116</b><a name="175116"> </a><a name="hc175116"> </a></p><p><b>contentType</b>: image/jpg</p><p><b>data</b>: (base64 data - 13525 bytes)</p></blockquote><hr/><blockquote><p><b>Generated Narrative: Binary #175117</b><a name="175117"> </a><a name="hc175117"> </a></p><p><b>contentType</b>: image/jpg</p><p><b>data</b>: (base64 data - 12810 bytes)</p></blockquote><hr/><blockquote><p><b>Generated Narrative: Binary #175118</b><a name="175118"> </a><a name="hc175118"> </a></p><p><b>contentType</b>: image/jpg</p><p><b>data</b>: (base64 data - 14441 bytes)</p></blockquote><hr/><blockquote><p><b>Generated Narrative: Binary #175119</b><a name="175119"> </a><a name="hc175119"> </a></p><p><b>contentType</b>: image/jpg</p><p><b>data</b>: (base64 data - 12533 bytes)</p></blockquote><hr/><blockquote><p><b>Generated Narrative: Binary #175121</b><a name="175121"> </a><a name="hc175121"> </a></p><p><b>contentType</b>: image/jpg</p><p><b>data</b>: (base64 data - 7166 bytes)</p></blockquote><hr/><blockquote><p><b>Generated Narrative: Binary #175120</b><a name="175120"> </a><a name="hc175120"> </a></p><p><b>contentType</b>: image/jpg</p><p><b>data</b>: (base64 data - 11377 bytes)</p></blockquote><hr/><blockquote><p><b>Generated Narrative: Binary #175122</b><a name="175122"> </a><a name="hc175122"> </a></p><p><b>contentType</b>: image/jpg</p><p><b>data</b>: (base64 data - 13281 bytes)</p></blockquote><hr/><blockquote><p><b>Generated Narrative: Binary #175123</b><a name="175123"> </a><a name="hc175123"> </a></p><p><b>contentType</b>: image/jpg</p><p><b>data</b>: (base64 data - 12887 bytes)</p></blockquote><hr/><blockquote><p><b>Generated Narrative: Binary #175124</b><a name="175124"> </a><a name="hc175124"> </a></p><p><b>contentType</b>: image/jpg</p><p><b>data</b>: (base64 data - 12430 bytes)</p></blockquote><hr/><blockquote><p><b>Generated Narrative: Binary #175125</b><a name="175125"> </a><a name="hc175125"> </a></p><p><b>contentType</b>: image/jpg</p><p><b>data</b>: (base64 data - 11420 bytes)</p></blockquote></div>
        </text>
        <contained>
          <Binary>
            <id value="175114"/>
            <contentType value="image/jpg"/>
            <data value="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"/>
          </Binary>
        </contained>
        <contained>
          <Binary>
            <id value="175115"/>
            <contentType value="image/jpg"/>
            <data value="/9j/4AAQSkZJRgABAQEAYABgAAD/4QDCRXhpZgAATU0AKgAAAAgAAwE7AAIAAAANAAAAModpAAQAAAABAAAAQJydAAEAAAAaAAAAoAAAAABPbGl2aWEgU3RhYWwAAAAEkAMAAgAAABQAAAB2kAQAAgAAABQAAACKkpEAAgAAAAMyNwAAkpIAAgAAAAMyNwAAAAAAADIwMjA6MDg6MTggMTM6MDU6MzEAMjAyMDowODoxOCAxMzowNTozMQAAAE8AbABpAHYAaQBhACAAUwB0AGEAYQBsAAAA/9sAQwAIBgYHBgUIBwcHCQkICgwUDQwLCwwZEhMPFB0aHx4dGhwcICQuJyAiLCMcHCg3KSwwMTQ0NB8nOT04MjwuMzQy/9sAQwEJCQkMCwwYDQ0YMiEcITIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIy/8AAEQgA9QINAwEiAAIRAQMRAf/EAB8AAAEFAQEBAQEBAAAAAAAAAAABAgMEBQYHCAkKC//EALUQAAIBAwMCBAMFBQQEAAABfQECAwAEEQUSITFBBhNRYQcicRQygZGhCCNCscEVUtHwJDNicoIJChYXGBkaJSYnKCkqNDU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6g4SFhoeIiYqSk5SVlpeYmZqio6Slpqeoqaqys7S1tre4ubrCw8TFxsfIycrS09TV1tfY2drh4uPk5ebn6Onq8fLz9PX29/j5+v/EAB8BAAMBAQEBAQEBAQEAAAAAAAABAgMEBQYHCAkKC//EALURAAIBAgQEAwQHBQQEAAECdwABAgMRBAUhMQYSQVEHYXETIjKBCBRCkaGxwQkjM1LwFWJy0QoWJDThJfEXGBkaJicoKSo1Njc4OTpDREVGR0hJSlNUVVZXWFlaY2RlZmdoaWpzdHV2d3h5eoKDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uLj5OXm5+jp6vLz9PX29/j5+v/aAAwDAQACEQMRAD8A9/ooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBrMFBJOABk1ydv4xur/AM6TT9Aurm2jlaITCaJQxU4JAZgcVo+LtSOleGL24U/vGTZHg8lm4FZvh+w/szQbO0P30jBc+rHkn8zQBY/4SPWP+hYuv/AmD/4ul/4SLWT/AMyvdf8AgTB/8XVsU8UxFIeINaP/ADK91/4FQf8AxdKNf1o/8yvdf+BUH/xdaC08UDM3+3tb/wChWuv/AAKg/wDi6P7d1v8A6Fa6/wDAqD/4utZacKQGP/bmuf8AQrXf/gTB/wDF0v8Abmuf9Crd/wDgTD/8VW2tSCgDK8Pa7Hr9g9ykElvJHI0UkUhBZXU4IyCR2rYrjNA/4lnjnXNM6R3O28iHQfMPmx+NdnQAUUUUAFFFFABRRRQAUUUUAFFFctrHiuaz16LR9N05b65MJnl3T+WsS5wATtbk88cUAdTRXGt421C3/wCPrwxeY9beVZP5haYvxI04MFn0nW4D3L2eQPxBNAHa0Vzlv440CfG69EJPadSn860YvEGjzj91qtk3sJ1/xoA0qKijuIZRmOVHB6bWBqWgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACimswRSzEADqSelcpqHjaCO+/s/SLSTVLzoTE2IUP+0/OPoAaAOrZlVSzEBRyST0qGO9tpTiO4jY+gYVxqaDquq3TT+IdVeSI/dsLQlI1+rDDP+lXD4Q0MjAsWjP96O4kU/mGoA64HNFcVL4UkTnTNc1KxPbMnnAfg9FtaeMtPORrVnqaDolzbmAn/gSbv5UAdrRXITeKdZ08f8TDw3I6jq1jcib9GVaks/iBo904SdLzT2Jx/psBjGfryKAOroqKGaK4iEkMiSxtyHRgQfxFS0AFFFFABRRRQAUUUUAFFFFABRRRQAVVv72LTtPuL2bPlQRtI+0ZOAMmrVZfiG0lv/Duo2kABmmt5EQE4yxUgUAcN4h1ubxG2kG20jUm05ZRcSnygCwx8uOfetX/AISNyf8AkB6r/wB+R/jWVpuvarYtHoJ0AtdWNtGHP2wKGG0AEfL7VpjW9c/6Fv8A8nh/8RTESDxI/wD0AtW/78j/ABpw8Sv/ANAHVv8AvyP8aYNb1z/oW/8AyeH/AMRThrmu/wDQtf8Ak+P/AIigCQeJXH/MB1b/AL8j/GnDxM3/AEAdX/78j/Goxrmu/wDQs/8Ak+P/AIinjXde/wChZ/8AJ8f/ABFAyQeJ3/6AGr/9+R/jTh4of/oX9X/78j/Gohruv/8AQsf+T4/+Ipw17xB28Mf+T4/+IoAmHil/+hf1f/vyP8aUeKZP+hf1f/vwP8ajGveIf+hYH/geP/iKUa74i/6Fhf8AwPH/AMRQBi6hqF9L4r0zV7XQdTVYVaKffEOUPpz1robPxbZ3V3c2rW13BPbhDIkseCAwJH8jVK98U65p9lLd3HhlVhhQu5+3DgD/AIBWTpdnqusare69JZLaQ38NuYY2mycKrcnj/aFAHotFFFIAooooAKKKKACiikJoAo6tqUGkaXcX9w4WOFS3Pc9h+dcb4Usp/s1xrF8pW+1J/OdW6on8K/lzTvFE7eIPE9t4fiJNpaYuL3nhj/Cv9a3iUiiLHCxouT6KAP8ACmIy7vVbqHWItPtLBrklPMmfeFEa5Azz169KvX109qqMlnNc7jgiJdxX3xRp15BqVpHeQKwjfIUsuCQDVwCgCnCba7tDNLYlBzlJoMPx/skZqgkGgarL9nGnsJME/PZvFwOvzFQK3RTskjBJoA4zUPD3hCC48m5uzZzYztF2YyPzqyvhO0sY1mh16/tozgqz3AZTnpya6aS0t5/9dBHJ/vIDS3FlbXlv9nubeOWHj5HUFeOnFAGTBYa0qA2ficSRj/npbq/6hqdI3jK35jm0+6A6BkMef51pWOm2emo6WVskCO25lRcAmmQaTBb3X2iOe8DZJKNcOyH/AICTigZjnXfG0J/eeGLSZf70N8ufyNWofFmqKP8ATfDGoxephTzR/wCO5q1eQa2dQWWyvLYWvAaCSLJ9yGqbUtattJntI7lJcXT+WjKm4B+wNAFY+N9LiUm5g1O2VRlmm0+ZVX6nbitvTtQtdUso7yylEtvIMo4BGfzrD8aXn2HwXq85PIt2QfVvlH86n8FWZsPB2lwNjcsClsepFIDoKKKKACiiigAooooAKKKQnAyelAC1gaz4q0/SGNsHNzqDD93ZwAvIx7ZC52j3OBWHqXiPUNevJ9M8Nv5Edu+y5v2GQD3VB3PvVzSdCstKZpYkL3Tj97cyHdI592PP4UwM9tP1nxTEG1+Q2NruytjbP8xH+2w/lXRWVjbWNukFrCkUajACjGfr61KoqVRQIFWpAtKop6rQMbtoK1MFpCtICArioJ7eGdWSaKORWGCGUHNW2FRstMDk28NXGjzy33hy6aCVvma0lO6J/Yf3a0tG8XxXE6WGsxf2ZqjcLDMcLL7ox4b6CtZhWZq2j2OsQCK+gWTadyN0dG9VbqD9KAOmorz+21zUfCMq2+uyyXmmyOEhvAMtF6B+5HvXeRyJMivGysjDKsDkEUgJKKKKACiiigAooooAKKKKACiiigDhtbH2P4j6fOOFvbNoWOOrK2R/Otwdaw/iCjLcaDPHIY5FvdgdeoDCrf2C7DH/AImU3/fIpiNUUorMFhd/9BOb/vkf4U8afef9BOb/AL5FAGotPFZQ0+8P/MUm/wC+RTxp15/0FJv++R/hQBrLThWSNOvf+grN/wB8j/CnjTr3/oKz/wDfIoGaymnispdOvf8AoKz/APfI/wAKcNNvf+grP/3yP8KQGV8QpivhZrVD+8u5kgUdzuODXUW0K29tFCv3Y0VB+AxXD+IrSYeIfDdtcXclxG93vKuBj5R7V3tABRRRQAUUUUAFFFITQAE1k6/rMWhaNc6hLg+UhKpn77dlH1NaTtgVwGryHxN4wi00fNpumES3Po0v8K++KAJ/CmmzWemNd3uW1G/c3NyW6qzc7foBgVZ1q70prK5stQvxAm1TKFfDhSeB0PXBGK1HkSJd8jqqkgZY45PavPvGGlrp9/pt/HIl002pL58UjAsxxhQB6KM/nTEddB4g0ODTreVL6KK1b5IiwK5x2xitBtRsFWMteQKJRujLSAbh6j1rzS+0++8XatdtpmnwtpkCNbQyyuqpC5+8+3OSQM9BWNDbJ4jvpNLs7d5Vt4Vis55HCpFEvDOec5OD2oGe3LhsYIORkY708KR1ryyTULttFv8AV4b+eKNnTT9LCHmTb8pbHuc81agufFC6vF4Zh1uM6k0H2iSe4TheOEXA5PqaBHpgFLXn/wDwkuuz6hcNaXFj/ZumALezTA7mK/eKgcnv2pdM8fXwndtV09Y7Z7U3kJiYFxHn5dwzwSKBnoAFPArnG8aaXFDYvMk6yXlu1wsIUM0ca9Wc5wBSS+PfD1rb2c93cyWy3il4VkiYsVzjJ2g4H1oA6YCs6G/t77WrqwFssjWIRmmYBgrsM7RxwQMfnVSDxp4cuPMEOqwyPGCzKFYNx14IrR0tbOW1+32kHlC+xcOWGGYlRgn3wBQBy3xPlL6DY6aOXv7+KLHtnJ/lXb2yrDbxxKAFRAoA9hXn/i9zefELw1p4+ZLcPdSL9B8p/MV3MEu6gC+DS1GpyKkpANZgqlicADJrI/4SnSM4+1DP+6a1Lj/j3l/3D/KvHx98f71AHsasGUMOQRkU6orf/j2i/wBxf5VLQAVgeM799N8J6hcRHEnl7UOehPFb9cl8R0LeC7ojPysrHHoDQBH4fsE03QbK1jGNsSsxxyzEZJPvk1rLVa1YNawsOjRoR/3yKsKaYiValWoVNSqaAJlqVahU1IrUDJ1x3pGxTQ1IWpAI1RNT2NRsaYERqNqkY1E1AiCaNJonjlRJI3G11YZVh6EVzmh3EnhPXk0SZ3fSLwlrOSQ8wt/zzz6enSumY1zPjWDzfDU868S2pE8bZ+6VNAHoVFVNNuDdaXaXLfemgR2+pUE1bpDCiikP3T9KAMeTxPpMUjo90AyEqw2ngitWGaO4hSWNtyOMqfUV5NqH/IRuv+ujfzr07Rf+QNaf9cxQBfooooAKKKKAOM+IYxZ6TJ026hH83pnNXrq/tLNwLm6ihL5Kh3C7vpmqfxGH/EhtXH8F9ExHryaxvEFpbXnjXw/HdwJLE0FwNrDIz8hFMR0A1vSv+gja/wDf1aeNc0r/AKCVp/39Wq48LaJ30q2/74pw8K6J0/sm2z/uUAWV1zSf+glaf9/Vp413Sf8AoJWn/f1arL4V0PvpNt/3xTx4U0PIH9kW3P8AsUDLI17SP+gnaf8Af1aeNe0j/oJ2n/f1arDwloffR7b/AL4pw8J6DjP9kWuP9ygCyuv6P/0FLT/v8tSJruku6ompWjO5CqolUliegqqPCOgd9Itf++K5zxboGlWMugizsYYJpdUgXci4OA24/wAqANHXh5nj3w3H/dWR+PYV2Nchf/vPibpKdfKs5H+mciuvpAFFFFABRRRQAUxmwKUmq00mBQBj+KddXQ9DuLwDdNgJAgPLuxwoH4nP4Vl+GNIfSdHRJm33U5824c9Wduf0rNdz4o8aqT82m6Odw9HuDwPrgZrotRju5dOmSxdI7l12o7DIXPemIgvNLGoajZ3Mk2be2JcQjkM/Zj9Kr/8ACJaUb26vRBi5uAwMmclCRglfQ1o6Zp0OlabBYwbjHCm3cxyWPUsT6k5NXAKAMldAhh8OSaLaTSW8bxsnmr98Z6n61hy+BHgF0dMvFhaa1W2UMuNigYYgjua7QCnAUAcifDMy6pp22NW03SbXFvCP+Ws2OWIrD1WDxBf3R8RyaLJbXdjC8NvBGCZJncbdx/2VBJr0wCnCgZ42dKdvD1rYQaXdWlzdI0l/PKhDMi/MQfqRT7m1XSvhRaOtuz6jqbqjsR87LnhfoBgYr2QZHQ1HJbQzPG8sSO0bbkLLnafUUAeUTaRJbxWel3UgOoamouL5/wDn1tYxwnsD0+oq3ocpEup+Lb23tTpEcDJbo/LKq/dC9huOK9Cu9C02+a6e4tlZ7qIQzOGIZkBztyDxz6VmR+AtBi0wabDbyRWvnrO0aysd7KcgEkk49qAMXwtoGl2+kwz6zbQ/2hrEjOqsmGUNztHtivQI41RFRAFVVCqB0AHQVm3MWnza7ZCZj9thRngQEgbehOK1HcRozt91QWP0FIDzNXGofFbVLgHctnbrAvsxOT+ma7yzzivPvBIN3daxqZBzdXrAN6qvA/nXotouAKYi+vSuC8RapqNvrk8UFzMka7dqoxwOK75elKUUnJVSfcUhnlZ1nVWUg3twQRggsazs969gnRfs8nyr9xu3tXkI/wBYP96mIvrrOqqoAvbgADAAY1q+HdU1G41y3jnupnjbduVmODxXdW6L9mi+VfuL29qlCKOigfQUDHVjeKbP+0PC+pWwGS8DY47jmtmmsgdWVuQRgikBxPhe8+2+GdOnzljCEb/eX5T+oraBrl9DjbQdZ1Dw/cfIrzNc2RPR42+8AfUNXSqaYiwpqRWqupqRWoAnVqkDVXDU4NQMsbqC1QZoLUgJGamE0hamFqYAxpjGgtUbNQIRjXL+LS999g0KElX1GYI7D+FByTXSs1c/br9r+KNqhGVtLIt9CxNAHd28KW9vFBGMJEgRR7AYFTUUUhnDeK9Rv7XVwltcyxx7AdqkgZrD/trVv+f24/76NeplVJyVBPuKQou0/KvT0pgeOuzM7O5LMxyxPc1dj1fVIo1SO7nVFGFVWOAKg1D/AJCF1/10b+den6MqnRrQlV/1Y7UCOE03VtUk1S1jku52RpFDAscEV6XTdi9lX8qdSGFFFFAHIfEcf8UoW7rcRsD6fN1rK1jjxh4YfuwmQ/Qqp/pWz8Qxnwbdn+66H/x4VheIJFXWfCdw5Cp57gsT0zFTEcvo2oXumX+pXd4s7hYLg2SnOC+en1qpbSa2vhz+y2W8hvY71JI2mBD7Wwfyya9bF/bg8XMf/fYpy31ttx9qj/77FAHl8drqVx4VS7eS5t746rJBJtznY7fMPoMVb1d206LxVpsbyiQ29uLZRnLbW+Yj8Otekrf22c/aY/T74p66hbAYF1Hj/fFAHj981yt9ZGxLMRbxlBbh8l9w3bPfGeta6tqx8TOALz+0Pt03nZ3bPs2Pl9sYr0wajbEYN1H/AN9inC/tcY+0xY9N4oGeUeG47ybTtXh1C6ubaV7RWtZ2DYWMStuH1Jxn2rVt7p71vCET2htguoswXnDBVb5hnnBr0YahbHrdRf8AfYrl9WnivPiH4bjjlRxGs8jbWzjCnFAE5/efFNf+mWnfzY119cfYjzPihqb/APPOyiXj35rsKQBRRRQAUUUjdKAIpGwK5Pxjrn9kaNI8Z/0mZhDAM4+duM/QV1E33TXHeK/Dw19LXM/kvbOzoSm4EkY5H4UwLXhvSU0nRYbcMssrDfNIvO9zySaWPS71PEEmoHUWa2kUJ9laPhQPQ5/XFee3PhPVbKUvaESsDwUuGiz+HSrVrqfiuyGyQXUaD0RZ8/kc0CPRLt9RR1+xWtrOmPmEtw0bZ9sKwqVZpVsjNPblZFUs0UTbzx2B4z+lefv481e1+/bxS46meF4P1K4/Wr1h8SYp2C3NnGp7/Z7hJT+QOaAOm03X4NRuvs4stQtpME/6TblBx75IrQmv7K2lEdxeW8MhGQssiqSPxNY0fjTRWAaV7m3H96e2dR+ZGKsx654b1M7V1HTbhum1pULflnNAGwjLIqvGwZWGVZTkH6GpNuOoqsbW3urB7aP/AI92TZ+6bGB7EdKq6ZoUelTF4bm6ePbtEcshYD3oGagFPArL1Aayku/T3tnjx/qZQVP/AH1Vm7ubi1tI5FtHuJOA6RckccketIC2BTwKq216s9m1y0M8Crncs0ZVhjqcHnFMsda03UZWis7yKWRRuZFb5lHuOtMBjR2DeIo3Z/8AT1gIRc9EJ5NN8S3gsPDOoXJONkDYPuRj+tNxpb+J0f7Qp1JYCgiD5wmecisP4o3PleDntwcNdzpCB3IJyf5CkBQ8B2hg8M2W770gMjcd2Nd1brhRWJo1t9nsbaEdEjVf0roIVwtMRMBTqQUtIYyRN8bJnG5SM/WuSHgOPdn+0H65/wBUP8a7CigBkaeXGqZztUDP0p9FFABRRRQBheI/D6a7aLsk+z30J321yo+aNvT3B7iuf0vWZGu30rVI/s2pQjGGPyTj+8h4z9O1dyzY61ieINFsNes/IugyMpDRzRnDxsOhB/pTAaGxTw1cuuq3+g3DW+upus14i1BFypHbeB936mughnjnhSWF0kjcZRlbKsPYigRbDU4NVcNTg1AEwagtUW6k3UATFqaWqMtTS1ADy1MLUhaqWoajaaZatc3s6RRLxuY9T6Adz7UAWJp0gieSV1jjUbmZjgKPUmsvwPG+pavqviIxulvcssNtvXBZF43fQmqVnpN54wlWfVkks9IRw8Nt915/Qv3A9q9DhRI41SNVVFGFVRgAUDJaKKKQBSHpS0UAcjceB0nuJJTfuN7FseVnGfxrprO3+yWcVuG3CNQucYzViigAooooAKKSigDmfH4z4K1HjOFU/wDjwquunWWqaZZC9t0uFSNHTcSMEqORir3jVd3g7VAO0JNVtHbdotg2MbreM/8AjopiIR4Z0T/nwT/vt/8AGnDwxon/AED0/wC+3/xrUWnLQBmf8IzoaruNhGAOpMj8f+PU9fDGhMARYRkHoRI/P/j1Zi6hHq3iW+t5Zlj0/SQu/LbQ0jAk7j6AVabxx4Yil8o61ZhgcfK4Kj8RxQMtJ4Z0Bs7bCNtvBxI/H/j1SDwroX/QOT/v4/8A8VWVr2rW1tpDeJNKuoZzbY3iNwySoTypx39K6m2nS6tYrmE7o5kV0PqrDI/nQBmjwnoR/wCYcn/fx/8A4qrVl4e0mwulurWySOdQVD7mJAPUcmtBacKQHJ6EfM+IfiSTqFSFAfoorsa47wr8/izxRL6XQTP0UV2FAC0UUUAFFFFAETrkVRnt89q0iKYVzQBhS2Oewqq2nc9BXSmIHtTTAD2/SmBy0mmBlwyqw9CM1m3HhXTLg5m061dv7xiXP54ruDbj0pjWo9KBHn7eELNVIiNzAPSG4dR+QOKybzwM0jFobmPd2M9ukpH4sCa9SazU9v0pjWQ9P0oA8rg8Oa5Yk+XdBgOggneD9FYD9KmmvPGFmu6G4vFVe7TLP/6ECa9KNgPT9KibTx6fpQB5vB8Q9esX2X7LNjrusjH+o4robP4j+coMmmIRjqlyM/kRXRtpwZcEZHoRVKfw/ZT586yt5PUtEpoAqL8TNFVttzBeRH18rcPzFalh4q8O3jh4LmJJGGMuu1qxJ/BmmSj5Ld7fjrA5T+VZknw8tmbKahqA/wBmV0kX8mWgDvbeLRTfPqEH2L7W4w8yld7D3PWuQ+ITi/17w3piFWDztM2DkYXFUf8AhBZ0GIbqzHoZLHB/NHWrWieBrm01+HVLu9hl8lGRY443HJ75Zmx+FAzsrOPGMCtNBgVDBFtAqyoxSAdRRRQAUUUUAFFFFABTSadTSKAK0zYHFZs8xGea05VyKzp4C2eKYGTdSiVGjkUPGwwysMhh7iuZfT7rTHD6DdG2j3Ze1f5om/3VPCfhiuqltGJPBqq9m3oaBGUPGcdoyxarZT2sh43oN6N+I6VpxeJdJlQOL6MA/wB44qJrJiCMHB6j1qs+jW8hzJawufVo1P8ASgC1P4r0eAHfeKcf3QTVF/H2jKwWMXcrHpsgOPzqVdKROEgjUf7KAU9bJ1GACB6CgCu3jSLI2aXfMD32YpG8dadG4S4tr6Jj6wEirYsn9DUi2b+9AGfJ42s5f3enW11dXDfdUxlVz7saZp2jTXt2t/r7rdzq26CAjMUP0XoW962ks2HQHFW4bVh2NAGhbyk45rSiY4FZ8EBGK0I1IFAyzRSL0paQBRRRQAUUUUAFJRRQAmaM0hpKAMfxYN3hLVFxn9w1Zfh593hzTWJyTbJz/wABrZ8Qrv8ADuopnGbd+fwrB8Ktu8K6Yen+jqP5imI21rE17xRb6G8dutvJd3sw/dwRDn6k9hW2vXmsTQNLeC+1LU7pc3d1cOAWH3EBwoU+mBmgDymZdVh1bUb7UdOkn068l3XdvBIcrjpkjkEc12lhN8P7jw5PqK6Ii2tsVSXdahnUnpz1P1qDS7g+DPH2p2uoLs07VnEkVyw+XdydpPTuR+Fa+ra8NH8Qad4fsdNsZbHVeXI4HJ+ckDgjFAzz3UUXVbW5tvCWnXFppcjB7iSZyEfHQDPQV6H4Z8X/AGOLT9F1iwks5PKSOCcHdFIAoA57dKq/EPWbODw//wAI5paRTXd2RGlvAAdi+uB0NdPZ+Ho38F2mi3w3slqqMxAJRwo5HuDQB0S09etZuhrcR6Pax3RJmjXy2ZurbSVBP1AB/GtJeopAcn4KO+98Rzf39Sf9OK63Nch4AG7TdSm7S6hOwP8AwIiuuoAkooooAKKKKACiiigAooooATFGKWigBMUm0U6igBmwelNMY9KlooAiMQ9KaYF9KnooArGBT2pptl9Kt0YoAqC3UdqkWECp8UUARquKkoooAKKKKACiiigAooooAKKKKAGMuaiaEHtViigCk1sp7VC1mp/hrSxSbaAMs2I/u002C/3a1ttJtHpQBk/YB/do+wD+7WttFG0UwMoWC/3acLEf3a09vtS7RSAzls1H8NTLbAdqt7aUCgCFYgO1SKuKfRQAUUUUAFFFFABSUtJQAU3NONNNACE0hNLSGgCjqwD6PeoRndA/Hrwa5nwc27whpnOcREH8GNdVefNZXA9YnH/jprkfBBz4Rsh/dLr+TGmI6NaSSUxJv8t3A67Bkj8KVactAHKeIda8N6hYvY6hb3N2eqwx2z7w3sSuAa4V/Cfi27uYNWs7F4obLAtLeaVfMKZ54z19a9pUU8UDPMfDV/4N0G6NzfQXlnq2SXa7hdmVu+0qCMV6LputWerLvsWllj/56GJ1X/x4Crgx6D8qeB6UASLTs4Un0BNNWm3L+XaTP/djZvyFIDlvh5z4VWQ/8tbiV/rlia63Ncp8PV2eB9N/2kLH8TXU0AT0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUlLSUAIaQ04000ANNIelOppFAEUih1ZGGVYFSPY1xZ0PX/D8xg0BrS601iziC9choWJyQrKASp9812xFNIpgcb53jYf8AMN0b/v8ASUfaPGw/5hmjf9/pK65lphFAHKfbPGw/5hmjf9/pKUX3jcf8wvRf+/0ldTijbQBzA1Dxv20vRf8Av9JThqPjj/oF6L/3+krpcU7FAHNDUfHP/QM0X/v9JUcqeMtXxZXn9nafZygrPNaszS7CMELuBAJ9cV1YFPUUAV9N0+30nToLC1VlggQIgZsnA9TVwdKaBT6AJ6KKKQBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFIaWigBKQ0tBoAaaaafimkUAMIphFS4pCtAERFNK1NtppWgCErSbam20baYEW2nBaftpdtADQKUCnBacFpAIBTsUYp2KAH0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFJS0UAJSYp1FADMUhFSUUARYoxUtFAEWKMVLRQBFijFS0UARYpakooAZilxTqKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAEopjBihCEBscEjIz9OK4Pw9q/jDX7zWY11HQooNPvWs0mXTJn85lALHH2gbcE4xk96OodLnoFFYOmP4hhur9dZexubeNEa3extXiZz824FWkbkYXGD3rR0u+/tPTYL37LdWnnIH8i7j2Sp7MuTg+1AF2iiigAooooASimMGMZCEBscEjIz9OK4TQ9Y8Zay+sGO80Ix6devaxkWEwFyVALc+cdnJ29GwQevSkB39Fc94O8Sp4t8MW2rpbtbtKWSSEtu2OrFWAbjIyODXQ03dMAoqC5uYbO1kubiRY4YlLO7HAUDqaq3+p/YRaYs7y5+0zrCDbxbvK3Ane/I2qMcntkUAaNFFFABRRRQAUUgqvc+d9lk8iRI5tp2PIhdVOOCVBUke2R9RSbsgRZorlvAWpanrPhePUtUuI5pLmWRomii8tfKDFUIXJIyBu5JPzda6mnsAUUUUAFFZttqD30+oWyWl3bPauI1muIcRykqGDJz8yjOD05BFY3gbU9V1jS7y91O6huVa9litXhg8lWiQ7NwXcx5YMeWPGKEDOrorktZ1LWI/HGh6XZXlutpdrJLcw/Z8yCOMZLbyxGCzIuNoPJ59Os7UdAFooooAKKKKACiis+51H7NqVnZfY7yX7SHPnxRbootoB+ds/LnPHrg0AaFFJWZr11LZaHe3UNzDatBC0nnzRGVUCjJJUMueAe4/HpSvoCNOisLwncaleeFdPvNXYG+uIRNKFUKF3chQB0wCB3PHU1SS+1d/iK2m/bYH02Ky+0vDHb7XRmbais5Y7s4duAv3R+La1sJPS51dFFFAwpK5LxfqWs2WoaDb6TeW8X2++W2kje33OyYLOysWwu1Vbgqckiuto6XAWiiigAooqs93Ct5HaGRRcOjOsfcqCAT9MkD8aALNFFZ+maidSt5JvsV5abJni2XUWxm2nG4DJyp6g9xQBoUUUUAFFJWL4pv59L8M6hf293DayW0LS+bPAZVAUZI2hlyT0HPU9D0pN6AjborI8OPqM3h3T5dVKtfyQJJPtAADsMkADsM4/DvWtTegk7i0VVvrr7FY3F15M0/kxs/lQJvd8DO1V7k9AKW0uPtdpDceTLCZY1fy5l2uuRnDDsR3FAyzRRRQAUUUUAFFFFABRRRQAUUUUAZmu6pHomg3+qSjMdpbvMR67VJx+NcF4W8PeKrHwPp8EepWIS8kSe7i+xP5+JnDSDzfNIyAx52du3Wuk8beF9S8V6YdLt9Yt7CylKmdWsmmeTa2cZ8xQFOBkYyfWuis4p4bSJLmSKSZVAd4YjGhPspZiB7ZNC0BnLfEe8vrLwuX0vULmy1CWeOC1EAQ+bI7BVDblPHJJxg8dah1e51C31rw14XS9ngt7mKRrm93/vZvKVf3aseQzE5LD5sA49a2Ne8Oya3qei3X23yY9NuWuDCYQ4lYoVBzkbSuSQcHntWDrkMnjO5m0rTJrDbpFyEubfVLUTx3D7VYZXIbaNwO7PJ7Ec0kHoQ6Ul/J8QNQ0zSdb1H+xbC3jaUSSi5H2piSY2klDORswSqsCM9RmneHtZkt38X+ILvULufSILjyrZZ5MjMKYkZRwFDPkYAA+WtLwnd6lm60K/0zTbKSzhj2zaS5NsSwI2qpUFGG3O054I5qrF8P5V8At4XfWNx8tkW5W22jDOWYsu47mYEqTkcE4xk0/IFa+pi3l5rVl8IbW/bVr+31m+lSZGRgzeZPJ8sWHDEKocfKuD8vB612Wn6RqKava6jc6vdmKO0MJ09iDHklcOx6s+FOSSeScYGcrqXhsand6I8t1i30y4NyYfLyJXCkLzn5QpbIGD0FdABii/YWuhna7qkeh6DqGqy/ctLd5iPXaCcfia8xjs/FHhb4VJdvqFv9l8o3d/FDbtFdqsp3SbZXd03jcf4B07Hmu38aeGtR8V6WNNt9WgsbN2VrhGs2laXawYLuEi4U4GRjJ9RVfVPCWqeI7P+z9e1yJ9NZlMltp1kbbzgpztdnkkO04HC7enWl0Hexo+H7DSz4Ls7TRBNaabPaAwGNisiK653ZOSH+bOTnmteytfsdlBbedNP5Uap5s7bnfAxlj3Y9zVaaxuRNpy2F6LO0tX/fW6wKwmj2kBATymDg5HpitKqfcSTS1OB8fabDr+veGtDczkT3TXE4juZI1EMS7jlVYDJYoAx5GeCKNl6PifY6XaazqLabZ2H2m5tpJQ6gk7IlLkb2JIdjuZicCt6Tw88njNPEH2z5VshaLb+Xyvz7iytuwN2ACNvIA5FN0rw4+n+I9Y1eS+Mx1GSNhH5W0xhE2hS2TuHU9Bye9JDeph6RdajefEPxHbJq15NY2iRR4k2hIHcbmC7VAJA2AbtxHzEnnnPt/EOp6V8L9Y8Q2zS3Je6nlsDcyGTy4Gl2IxLEkqBl8E9PQV1dl4aey0XV7KO9/0rUpZ5nuxFyjSZCnaSc7V2qOedvaqF35ej6Tp3g2zvRb3t3ZtBa3LxrsjCKFLbTwTyML3556mjyDr5GN4gtr7TJfD8OkeINUm1vULmNJ3F15qyW+MyyiFw0SAAAgqgAJA5zz6JbxPDbRxPcSTuigNLKFDOfU7QFyfYAe1cBoVrq/g3U7LTpdH8PSWt5KsPn6VGbef7vLvG2d4BHLBunOK6jS5tSuPEGrvLdJNpI8tLRVi2lHAIkG7+IZ289M5HY091oIt69rFt4f0S81W73GG2jLkL95j0Cj3JIA9zXE+J11O08FyanqGpXEeu3gEFtbxTOkETykIsQjU4fAPLMGbIJG3gDsPE2hReI9BuNLmlaESFWWVBkoysGU474KjjvVLUPDFzqr6TNe6krXFjcrcOY7fakm1SMKpY7eSGyS3Kikl3HsZeoaxb+HrnQ/BtpfQWDNbbnnYruSFAFCxqfvSMenBwAxwcVJpNtdjUtXvobvVbTRGtQsTXkzySGXLFpkE24xqBgBSApIztxjOlqfhy4m8RQ69pV9HZ6ilubWQz25njli3bgpUOpBDcghh15BqTWPD9xq2hanp51SWOa/h8lp9uRGp4IVMgDgkZznnknAob08wsro5nwjZa74j8Gabd3Ov6hbmS4W780bd9xHv3BG4G1SgUfLtydxIIOD3OpMF0u5druSzCxlmuI9u6IAZLDcGXI9wRU1paxWNnBaQKFhhjWONfRVGAPyFZ/ifRpPEPhu/0iO7No15CYvOCb9oPX5cjORkdR1olqtAjvqcVpWsanpXwfuvEGoXtzdahdRPPbm4bLfOdsCgAAAkbDgAZJPrU/hrRrDVbG30xLvVbX+wkSzuIre8ntTM5RXLMqMvBLE5wGJzkjGK39S8Lf2jYaTZSXYS2sbqK4kQRcSiMfKgG4bV3BT36fjU0Hh02/inUNYivWWG/ihWa2CEfvI8gOGz0KkAjHO0c9qbtqLU4yXVLebx5qQmNwIS0OgWc6vIBG7KZJGMisGDE7V+VtxKjJHWtXVLy28GNpmjWus3C3uqybDearfvOY0QZZ1EjEbzkKqqACxGQcYq2PAYHhI6QNRxem+/tD7cID/r/N8zcU3cj+HG7pV7VvDM17qVhq1lqAttWst6rNLB50bo+NyMm5TjgYwwIx1POUtkhve5R0W3u5PFhvLGfVP7HW2ZJ2v5pGW5mLDa0aOfkCgNllVQ24YyOa1fFviKLwt4dn1OTyyylY4llcIrSMQqhmPRcnJPYAmr9rZzxy+fdXbTzsoUhFKRL67UycZPOSWPbOKqeJPD8PiLS1s5JWgkimS4gmRQTFKjblbB4PPUHqCaGC3ZzHlXuo3+kvpuq6hd3aTpLe36Sull5PJZEjz5b7vurgMwBBLdCU0s6xqvjDxVaQ63ffY4GS3jlIjP2Z2XewQBQpI3IBuDEANk5PPWWVjqP7l9U1FbiWIkgWkBt43PQFlLMScdt2O+OmIfDOgDw/pstu1wbmee5lup5ym0yO7FumTjAwOvagWti5o9lNp2j2lncXkt5NBEqPczH5pWAwWbk8n6muV0J9Ru/iRr2dYvbnS7CNIlhkKBFnkG9lARRkKm0Ddk5Y5JNd1XOeHfDUugw6irah9omvbua6Mhh24ZzkbhuO4qAADkcDoKV3e4+ljmvDepXUtt4qvr7Wb250uzu5YxcTMFby4l+YKUVQPmL5ZQDgKAcjinqM+oH4V6BpN/NPLqGtyQ20m8tJJ5bku4PVmIjBUk8+9dQ3gwf8ICPC0d8VVowk1yYdxlJbdISu7+I7u/G7vV248Oi48SaTqslzuj02CWOOAx9ZH2jfnOBhQQBjv1p6B5mZollp/iNo/EUF5qscLPsjs01CeOOMxsVO6NX25yvKgbfUHkmLw9MLv/AISTxE9yIori7aKOcKCUggGw4zx94SsD/tZwelamj+G30ldSjiv3MFzdS3MEYQjyWkHzAnJ3DcWIGAOehwDVRfBhX4fSeFV1FkaSz+yG7WHHY5bZu75JPPOTz0wtbMFbZnNW2valpPwkn1SW6upr/U5JDpyzyM8iiZ9sIz14DK3tnA7V0Ml1ex3ml+EbC9lN1HaLNf30jeZIkS4UEFs5d2zgnOAGPpU974Qe+t9GjfUAradcRTMFtx5cgjUgKq7vkG4hurcqM5wMWX8OTR+K31yz1AQm4tltrmJ4PMLhCxRkbcNrDcc5DA+lMWpgWNpDJ8TpEhvJ57TRLEswuJ3mMVxOefmck/cTpnADcYzVS38Rw+LdLu76K6vbkSSPHp+n6TcPHIu3IDSyRsCjNjdh2VQpUYJPPWaP4Zj0q51iRrlp01KfzWVlwVXYq7S2SW+6Tnj7x781W0Twzf6Jp66RDrIOkRArbotttuI0znaZdxUgcjOwHHfPNHqVfXQ5/UW8QWd/4K0t9YupdQkUm+ijKrHMI1BZmIXd94oCQcbd3HPN/W9QuPBFleXt3rv2q41W8jgtPt7LHBakrg9CAEX5mPQkAAkn5juQ+HUi8WNrr3LS7bFbOCFlJ8pQxZm3EksW+Xtn5epzR4j8PLr0Vm8dybW9sZxc2s+wOEcAj5lJG5SCQRkH0IPNDYkYdvb3l54k02bTL7VZ4oGZtSvLiR1t512kBEiJCEliDuRcAKQWzxVbwho9vf8AjDxH4k3XnF6bO1JvZmBWMYfILkMu9mwpBC7eAK6+0sb4bZdQ1AT3CKVAt4jDCCe+wsxJx/eYj0Aqp4T8PN4Z0KHTXu/tJjLEyiPZvLMzFiCzfMS3Jzz6CjZieqG+NbttP8H6pfLf3Nk1vA0gltwm8sBwo3qw5OB0zzwRU/hS2vrTwxp0ep3MtzfmEPcSytuYyN8zD2AJwAOAAKi8VeH38S6VDYrdi3RLqGd90XmCVUYNsIyOCQOc1uRIY4wpdnI6s3U0dBs4nxU+qTeNfDunaZql1AJmea6hQoI/JjwST8u4ksyL97GMjHJqGe/OifESZV1C6bTYtIkvNSWedpEiKsAjKGJCEgP8q4BxnFR2Canrvj7XNY0vUbS3hstmlp9otGnDbRvkKlXXadzgdT93kcVvS+ELO50PVtOnnnlm1ZWF3duR5jkjAxgYCqOFUcAD3JJqkg0uYeoXV/J4JvPFeo3V1Z3ItnubG1imaNYMqfLVlUgSO2VyHyMnAAxzW8SpdW3g7w34bu557u61CaCG8dy0kkiIPMmJ6k527ef71beoeErzVvDtnpmo6tFJLazQSebFaFEcRuGwU3nkgYJ3YHUAdK0pPD/n+LLPW5rretpZvbxQtHyHcqWk3ZxkhQMbfXntT0uJGPpNlY+IrRfFMOqatbxXUe+KKPUJVjt9uRkxlihYEcqVKcY2nknnNP1bUpPhFf6zd6lfzPMJjaSmRo5ZmZikIBXaVH3Pu7csSenXq7bwhcWnh7VtHg1Rkju3uDbOIj/oyzEkgjd8+0s2D8vXp3q1qXhaO80vSNNt5xbWunTwShPLDh1i+6vJGOQpzz93pRv8xmB4yOs22geH9PtNbvbXVrqeGzJh2fvSQDI7EqW+VVc/KV5POeKl1+5v4/iH4e0yw1O72SQSzT2mVMZVAArMQu7lmyctg7MYyedvUvDb6l4l0nVvt5SPTopkEHl7izOAu8Nn5WABHQ9T0qzb6GsXie+1ySfzZbi3jto02Y8pFLMRnJzuLZPA6Cj1FsjD0e4uT4z8SPFc3dzZ2cEEJjklLK1xtZ22g/KvysgIUAZ7ZrnH1G6u/hrN4uvNYvo9YmR2s4rW5ZI4pSxWOEQqdsjZwCGViTnpXUKIPAmk3Vze3TXLXuol94jEYDzSYXcckADIBYnoo47Hnn0vXfB80+vNaeGtX3l5ZZxbm2vZNxBCI4DK5wMAYXOBS30H1NG91++0DTtC0rUNZA1jVmBkub7yl+zKFBcKFVVZskKikElm53AYq1pVrdzeJ5LyxutWj0hbR45pbyZ2FxMWG1o0kyFCgE7lVVbcMAitLV/D8mq6hputWF39g1SzRljeaDzUZHA3I6blJ6DkMCCOvark2l3lxp92kmot9tuLdoVlWMiKIkY3LHu9eeWJ7ZxQ2JJdzgtF1e9k+HGt61f6tf3Nssl00EzSbJZUBKRqpQLtHAOV2ks3YDn0Hw/DeW/h7TYdQlea9jto1nkc5ZnCjcSe5zmsy88Iwz+F9N0GC48i2sZLdsmPd5ixMG2kZH3ioyf510iLsQLknAxk9TTdg3JKKKKQwooooAKKKKACszUvD2i6w6yanpGn3zIPla6tklK/QsDiiigC9BbQ2sKQ28McMSjCpGoVR9AOBUtFFABRRRQAUUUUAFFFFABRRRQAVUvbCz1K3a2v7SC6gb70U8auh/BgRRRQBFpujaVpCtFpmmWdijcsttAsYJ9woHpWhRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUUsMdxC0UyLJG64ZHUEMD1BHcUUUAUNN8O6Jo8rS6Xo+n2MjrhntbVIiw9CVAyK1KKKACiiigAooooAKKKKAI5I0mRo5EV1IwQwyD+FZ1h4Z0HSpjPpuiabZzMMGS3tEjY/ioFFFAGrRRRQAUUUUAFFFFABRRRQB/9k="/>
          </Binary>
        </contained>
        <contained>
          <Binary>
            <id value="175116"/>
            <contentType value="image/jpg"/>
            <data value="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"/>
          </Binary>
        </contained>
        <contained>
          <Binary>
            <id value="175117"/>
            <contentType value="image/jpg"/>
            <data value="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"/>
          </Binary>
        </contained>
        <contained>
          <Binary>
            <id value="175118"/>
            <contentType value="image/jpg"/>
            <data value="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"/>
          </Binary>
        </contained>
        <contained>
          <Binary>
            <id value="175119"/>
            <contentType value="image/jpg"/>
            <data value="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"/>
          </Binary>
        </contained>
        <contained>
          <Binary>
            <id value="175121"/>
            <contentType value="image/jpg"/>
            <data value="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"/>
          </Binary>
        </contained>
        <contained>
          <Binary>
            <id value="175120"/>
            <contentType value="image/jpg"/>
            <data value="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"/>
          </Binary>
        </contained>
        <contained>
          <Binary>
            <id value="175122"/>
            <contentType value="image/jpg"/>
            <data value="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"/>
          </Binary>
        </contained>
        <contained>
          <Binary>
            <id value="175123"/>
            <contentType value="image/jpg"/>
            <data value="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"/>
          </Binary>
        </contained>
        <contained>
          <Binary>
            <id value="175124"/>
            <contentType value="image/jpg"/>
            <data value="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"/>
          </Binary>
        </contained>
        <contained>
          <Binary>
            <id value="175125"/>
            <contentType value="image/jpg"/>
            <data value="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"/>
          </Binary>
        </contained>
        <identifier>
          <system value="https://www.indlaegssedler.dk/Indlaegssedler/Indlaegsseddel/"/>
          <value value="37144"/>
        </identifier>
        <status value="final"/>
        <type>
          <coding>
            <system value="https://spor.ema.europa.eu/v1/lists/100000155531/terms/"/>
            <code value="100000155538"/>
          </coding>
        </type>
        <subject>
          <reference value="MedicinalProductDefinition/IBD-MPD-2"/>
        </subject>
        <date value="2021-07-20"/>
        <author>
          <identifier>
            <system value="https://medicin.dk"/>
            <value value="medicin.dk"/>
          </identifier>
        </author>
        <title value="Hyrimoz 40 mg injektionsv√¶ske, opl. i pen"/>
        <section>
          <title value="Indl√¶gsseddel: Information til patienten"/>
          <code>
            <coding>
              <system value="https://spor.ema.europa.eu/v1/lists/200000029659/terms/"/>
              <code value="200000029894"/>
            </coding>
          </code>
          <text>
            <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                     <a name="Section0"/>
                     <h2>  Indl√¶gsseddel: Information til brugeren  </h2>
                     <h3>Hyrimoz 40 mg injektionsv√¶ske, opl√∏sning i fyldt pen</h3>
                     <div class="paragraph">Adalimumab</div>
                     <div class="paragraph">
                        <br/>‚ñº Dette l√¶gemiddel er underlagt supplerende overv√•gning. Dermed kan der hurtigt tilvejebringes nye oplysninger om sikkerheden. Du kan hj√¶lpe ved at indberette alle de bivirkninger, du f√•r. Se sidst i <a href="#Section4" title="Anchor link til afsnit - punkt 4">punkt 4</a>, hvordan du indberetter bivirkninger.</div>
                     <h3>  L√¶s hele denne indl√¶gsseddel grundigt, inden du begynder at bruge dette l√¶gemiddel, da den indeholder vigtige oplysninger.  </h3>
                     <ul>
                        <li>Gem indl√¶gssedlen. Du kan f√• brug for at l√¶se den igen. </li>
                        <li>Din l√¶ge vil ogs√• udlevere et <b>patientkort</b>, der indeholder vigtige sikkerhedsinformationer, som du skal v√¶re opm√¶rksom p√• f√∏r og under din behandling med Hyrimoz. Opbevar <b>patientkortet </b>p√• dig under din behandling og i 4 m√•neder efter din (eller dit barns) sidste injektion af Hyrimoz. </li>
                        <li>Sp√∏rg l√¶gen eller apotekspersonalet, hvis der er mere, du vil vide. </li>
                        <li>L√¶gen har ordineret dette l√¶gemiddel til dig personligt. Lad derfor v√¶re med at give medicinen til andre. Det kan v√¶re skadeligt for andre, selvom de har samme symptomer, som du har. </li>
                        <li>Kontakt l√¶gen eller apotekspersonalet, hvis du f√•r bivirkninger, herunder bivirkninger, som ikke er n√¶vnt i denne indl√¶gsseddel. Se <a href="#Section4" title="Anchor link til afsnit - punkt 4">punkt 4</a>. </li>
                     </ul>
                     <div class="paragraph">
                        <br/>Se den nyeste indl√¶gsseddel p√• <a href="https://www.indlaegsseddel.dk" title="null">www.indlaegsseddel.dk</a>.</div>
                     <h3>  Oversigt over indl√¶gssedlen  </h3>
                     <ol>
                        <li>Virkning og anvendelse </li>
                        <li>Det skal du vide, f√∏r du begynder at tage Hyrimoz </li>
                        <li>S√•dan skal du tage Hyrimoz </li>
                        <li>Bivirkninger </li>
                        <li>Opbevaring </li>
                        <li>Pakningsst√∏rrelser og yderligere oplysninger </li>
                        <li>Brugsvejledning </li>
                     </ol>
                  </div>
          </text>
          <section>
            <title value="1. Virkning og anvendelse"/>
            <code>
              <coding>
                <system value="https://spor.ema.europa.eu/v1/lists/200000029659/terms/"/>
                <code value="200000029895"/>
              </coding>
            </code>
            <text>
              <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                        <a name="Section1"/>
                        <div>¬†</div>
                        <h2>1. Virkning og anvendelse</h2>
                        <div class="paragraph">Hyrimoz indeholder det aktive stof adalimumab, et l√¶gemiddel, som virker p√• din krops immunforsvar.</div>
                        <div class="paragraph">
                           <br/>Hyrimoz er beregnet til behandling af inflammatoriske sygdomme beskrevet nedenfor:</div>
                        <ul>
                           <li>reumatoid artrit </li>
                           <li>polyartikul√¶r juvenil idiopatisk artrit </li>
                           <li>entesopatirelateret artrit </li>
                           <li>ankyloserende spondylitis </li>
                           <li>aksial spondyloartritis uden radiografiske tegn p√• AS </li>
                           <li>psoriasisartrit </li>
                           <li>psoriasis </li>
                           <li>hidrosadenitis suppurativa </li>
                           <li>Crohns sygdom </li>
                           <li>colitis ulcerosa og </li>
                           <li>ikke-infekti√∏s uveitis. </li>
                        </ul>
                        <div class="paragraph">
                           <br/>Det aktive stof i Hyrimoz, adalimumab, er et monoklonalt antistof. Monoklonale antistoffer er proteiner, som binder til et bestemt m√•l i kroppen.</div>
                        <div class="paragraph">
                           <br/>M√•let for adalimumab er et andet protein kaldet tumornekrosefaktor (TNFŒ±) som er involveret i immun (forsvars) systemet og er til stede i √∏gede m√¶ngder ved de inflammatoriske sygdomme n√¶vnt ovenfor. Ved at binde sig til TNFŒ± blokerer Hyrimoz dets virkning og reducerer den inflammatoriske proces ved disse sygdomme.</div>
                        <div class="paragraph">
                           <br/>
                           <b>Reumatoid artrit</b>
                        </div>
                        <div class="paragraph">Reumatoid artrit er en bet√¶ndelsessygdom i leddene.</div>
                        <div class="paragraph">
                           <br/>Hyrimoz bruges til at behandle reumatoid artrit hos voksne. Hvis du har moderat til alvorlig aktiv reumatoid artrit, vil du evt. f√∏rst f√• andre sygdomsmodificerende antireumatiske l√¶gemidler, s√•som methotrexat. Hvis du ikke responderer tilstr√¶kkeligt p√• disse l√¶gemidler, kan du f√• Hyrimoz til behandling af din reumatoide artrit.</div>
                        <div class="paragraph">
                           <br/>Hyrimoz kan ogs√• anvendes til behandling af alvorlig aktiv og progressiv reumatoid artrit, der ikke tidligere er behandlet med methotrexat.</div>
                        <div class="paragraph">
                           <br/>Hyrimoz har vist sig at kunne neds√¶tte hastigheden for √∏del√¶ggelse af brusk og knogler i leddene for√•rsaget af sygdommen og at forbedre de fysiske funktioner.</div>
                        <div class="paragraph">
                           <br/>Normalt gives Hyrimoz sammen med methotrexat. Hvis din l√¶ge ikke mener, at behandling med methotrexat er hensigtsm√¶ssig, kan Hyrimoz anvendes alene.</div>
                        <div class="paragraph">
                           <br/>
                           <b>Polyartikul√¶r juvenil idiopatisk artrit og entesopatirelateret artrit<br/>
                           </b>Polyartikul√¶r juvenil idiopatisk artrit og entesopatirelateret artrit er sygdomme med bet√¶ndelseslignende (inflammatoriske) reaktioner i leddene, som oftest viser sig f√∏rste gang i barndommen.</div>
                        <div class="paragraph">
                           <br/>Hyrimoz bruges til at behandle polyartikul√¶r juvenil idiopatisk artrit hos b√∏rn og unge i alderen fra 2 til 17 √•r og entesopatirelateret artrit hos og unge b√∏rn i alderen 6-17 √•r. Patienter skal f√∏rst behandles med anden sygdomsd√¶mpende medicin s√•som methotrexat. Hvis disse l√¶gemidler ikke virker godt nok, vil patienterne f√• Hyrimoz til behandling af deres polyartikul√¶r juvenil idiopatisk artrit eller entesopatirelateret artrit.</div>
                        <div class="paragraph">
                           <br/>
                           <b>Ankyloserende spondylitis og aksial spondyloartritis uden radiografiske tegn p√• ankyloserende spondylitis<br/>
                           </b>Ankyloserende spondylitis og aksial spondyloartritis uden radiografiske tegn p√• ankyloserende spondylitis er en inflammatorisk (bet√¶ndelseslignende) sygdom i rygs√∏jlen.</div>
                        <div class="paragraph">
                           <br/>Hyrimoz bruges til at behandle disse sygdomme hos voksne. Hvis du har ankyloserende spondylitis eller aksial spondyloartritis uden radiografiske tegn p√• ankyloserende spondylitis, vil du f√∏rst f√• anden medicin. Hvis denne anden medicin ikke virker godt nok, kan du f√• Hyrimoz for at mindske symptomerne p√• din sygdom.</div>
                        <div class="paragraph">
                           <br/>
                           <b>Plaque-psoriasis hos voksne og b√∏rn<br/>
                           </b>Plaque-psoriasis er en inflammatorisk hudlidelse, som for√•rsager r√∏de, sk√¶llende, skorpede pletter p√• huden d√¶kket med s√∏lvfarvede sk√¶l. Plaque-psoriasis kan ogs√• p√•virke neglene. Det f√•r dem til at smuldre, blive fortykkede og l√∏fte sig fra neglelejet, hvilket kan v√¶re smertefuldt. Psoriasis formodes at v√¶re for√•rsaget af et problem med kroppens immunsystem, som f√∏rer til √∏get produktion af hudceller.</div>
                        <div class="paragraph">
                           <br/>Hyrimoz bruges ogs√• til at behandle moderat til alvorlig plaque-psoriasis hos voksne. Hyrimoz bruges ogs√• til at behandle alvorlig plaque-psoriasis hos b√∏rn og unge i alderen 4 til 17 √•r, hos hvem l√¶gemidler p√•f√∏rt huden og lysbehandlinger enten ikke har virket godt nok eller ikke er egnet.</div>
                        <div class="paragraph">
                           <br/>
                           <b>Psoriasisartrit<br/>
                           </b>Psoriasisartrit er en bet√¶ndelsessygdom i leddene, som er forbundet med psoriasis.</div>
                        <div class="paragraph">
                           <br/>Hyrimoz bruges til at behandle psoriasisartrit hos voksne. Hyrimoz kan neds√¶tte hastigheden for √∏del√¶ggelse af brusk og knogler i leddene for√•rsaget af sygdommen og at forbedre den fysiske funktion.</div>
                        <div class="paragraph">
                           <br/>
                           <b>Hidrosadenitis suppurativa hos voksne og unge<br/>
                           </b>Hidrosadenitis suppurativa (kaldes somme tider svedkirtelbet√¶ndelse) er en langvarig, ofte smertefuld bet√¶ndelseslignende (inflammatorisk) hudsygdom. Symptomerne kan v√¶re √∏mme knuder i huden (noduli) og abscesser (bylder), som kan udt√∏mme pus.</div>
                        <div class="paragraph">Sygdommen p√•virker oftest bestemte omr√•der af huden, s√•som under brystet, i armhulerne, p√• inderl√•rene, i lyskeomr√•det og p√• balderne. Der kan ogs√• forekomme ar i de ber√∏rte omr√•der.</div>
                        <div class="paragraph">
                           <br/>Hyrimoz bruges til at behandle hidrosadenitis suppurativa hos voksne og unge fra 12 √•r. Hyrimoz kan neds√¶tte antallet af knuder og bylder og lindre den smerte, som ofte er forbundet med sygdommen. Du kan blive tilbudt anden medicin f√∏rst. Hvis denne anden medicin ikke virker godt nok, vil du blive tilbudt Hyrimoz.</div>
                        <div class="paragraph">
                           <br/>
                           <b>Crohns sygdom hos voksne og b√∏rn<br/>
                           </b>Crohns sygdom er en inflammatorisk sygdom i tarmen.</div>
                        <div class="paragraph">
                           <br/>Hyrimoz bruges til at behandle Crohns sygdom hos voksne og b√∏rn i alderen 6-17 √•r. Hvis du har Crohns sygdom, vil du f√∏rst f√• anden medicin. Hvis du ikke har tilstr√¶kkelig effekt af denne medicin, vil du blive tilbudt Hyrimoz for at mindske sygdomstegn og symptomer p√• din Crohns sygdom.</div>
                        <div class="paragraph">
                           <br/>
                           <b>Colitis ulcerosa<br/>
                           </b>Colitis ulcerosa er en inflammatorisk (bet√¶ndelseslignende) sygdom i mave-tarm-kanalen.</div>
                        <div class="paragraph">
                           <br/>Hyrimoz bruges til at behandle colitis ulcerosa hos voksne. Hvis du har colitis ulcerosa, vil du f√∏rst f√• anden medicin. Hvis denne anden medicin ikke virker godt nok, kan du f√• Hyrimoz for at mindske symptomerne p√• din sygdom.</div>
                        <div class="paragraph">
                           <br/>
                           <b>Ikke-infekti√∏s uveitis hos voksne og b√∏rn<br/>
                           </b>Ikke-infekti√∏s uveitis er en bet√¶ndelseslignende (inflammatorisk) sygdom, som p√•virker bestemte dele af √∏jet. Inflammationen kan f√∏re til nedsat syn og/eller fluer i √∏jet (sorte pletter eller sv√¶rm af uklarheder i √∏jet, som bev√¶ger sig i synsfeltet). Hyrimoz virker ved at reducere denne inflammation.</div>
                        <div class="paragraph">
                           <br/>Hyrimoz bruges til at behandle</div>
                        <ul>
                           <li>voksne med ikke-infekti√∏s uveitis (regnbuehindebet√¶ndelse), som p√•virker den bagerste del af √∏jet.</li>
                           <li>b√∏rn fra 2 √•r med kronisk ikke-infekti√∏s uveitis med inflammation, som p√•virker forreste del af √∏jet.</li>
                        </ul>
                     </div>
            </text>
          </section>
          <section>
            <title value="2. Det skal du vide, f√∏r du begynder at tage Hyrimoz"/>
            <code>
              <coding>
                <system value="https://spor.ema.europa.eu/v1/lists/200000029659/terms/"/>
                <code value="200000029896"/>
              </coding>
            </code>
            <text>
              <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                        <a name="Section2"/>
                        <div>¬†</div>
                        <h2>2. Det skal du vide, f√∏r du begynder at tage Hyrimoz</h2>
                        <h3>  Tag ikke Hyrimoz  </h3>
                        <ul>
                           <li>hvis du er allergisk over for adalimumab eller et af de √∏vrige indholdsstoffer i Hyrimoz (angivet i <a href="#Section6" title="Anchor link til afsnit - punkt 6">punkt 6</a>). </li>
                           <li>hvis du har en alvorlig infektion, herunder tuberkulose, sepsis (blodforgiftning) eller andre opportunistiske infektioner (us√¶dvanlige infektioner, som er forbundet med et sv√¶kket immunforsvar). Det er vigtigt, at du informerer l√¶gen, hvis du har symptomer p√• infektioner, f.eks. feber, s√•r, tr√¶thedsfornemmelse, tandproblemer (se ‚ÄùAdvarsler og forsigtighedsregler‚Äù). </li>
                           <li>hvis du lider af moderat eller alvorlig hjertesvigt. Det er vigtigt at informere l√¶gen, hvis du har eller har haft en alvorlig hjertesygdom (se ‚ÄùAdvarsler og forsigtighedsregler‚Äù). </li>
                        </ul>
                        <h3>  Advarsler og forsigtighedsregler  </h3>
                        <div class="paragraph">Kontakt l√¶gen eller apotekspersonalet f√∏r anvendelse af Hyrimoz.</div>
                        <div class="paragraph">
                           <br/>
                           <b>Allergiske reaktioner</b>
                        </div>
                        <ul>
                           <li>Hvis du f√•r allergiske reaktioner med symptomer som trykken for brystet, hv√¶sende vejrtr√¶kning, svimmelhed, h√¶velser eller udsl√¶t, s√• undlad at injicere mere Hyrimoz, og kontakt straks l√¶gen, da disse reaktioner i sj√¶ldne tilf√¶lde kan v√¶re livstruende. </li>
                        </ul>
                        <div class="paragraph">
                           <b>
                              <br/>Infektioner</b>
                        </div>
                        <ul>
                           <li>Hvis du har en infektion, herunder langvarig eller lokaliseret infektion (f.eks. bens√•r), b√∏r du kontakte din l√¶ge, f√∏r du begynder at bruge Hyrimoz. Kontakt l√¶gen, hvis du er i tvivl. </li>
                           <li>Infektioner kan opst√• lettere under behandling med Hyrimoz. Risikoen kan stige, hvis din lungefunktion er nedsat. Disse infektioner kan v√¶re alvorlige og inkluderer tuberkulose, infektioner for√•rsaget af virus, svampe, parasitter eller bakterier eller andre us√¶dvanlige infektionsorganismer og sepsis (blodforgiftning). </li>
                           <li>I sj√¶ldne tilf√¶lde kan disse infektioner v√¶re livstruende. Det er vigtigt at informere l√¶gen, hvis du f√•r symptomer som feber, s√•r, tr√¶thedsfornemmelse eller tandproblemer. Din l√¶ge kan anbefale midlertidig afbrydelse af behandling med Hyrimoz. </li>
                        </ul>
                        <div class="paragraph">
                           <b>
                              <br/>Tuberkulose</b>
                        </div>
                        <ul>
                           <li>Eftersom der har v√¶ret rapporteret tilf√¶lde af tuberkulose hos patienter i behandling med adalimumab, vil l√¶gen unders√∏ge dig for tegn og symptomer p√• tuberkulose, f√∏r behandling med Hyrimoz p√•begyndes. Dette vil omfatte en omhyggelig gennemgang af din sygdomshistorie og screeningstests (f.eks. r√∏ntgenunders√∏gelse af lunger og en tuberkulintest). Disse unders√∏gelser og resultaterne heraf b√∏r registreres p√• dit patientkort. Det er meget vigtigt at informere l√¶gen, hvis du nogensinde selv har haft tuberkulose, eller hvis du har v√¶ret i t√¶t kontakt med nogen, som har haft tuberkulose. Tuberkulose kan udvikles under behandlingen, ogs√• selv om du har f√•et forebyggende behandling mod tuberkulose. Hvis der viser sig symptomer p√• tuberkulose (vedvarende hoste, v√¶gttab, sl√∏vhed, let feber) eller anden form for infektion under eller efter behandlingen, b√∏r l√¶gen straks informeres. </li>
                        </ul>
                        <div class="paragraph">
                           <b>
                              <br/>Rejse/gentagne infektioner</b>
                        </div>
                        <ul>
                           <li>Fort√¶l din l√¶ge, hvis du har haft fast bop√¶l eller rejst i omr√•der, hvor svampeinfektioner som histoplasmose, kokcidioidomyse eller blastomykose er almindelige. </li>
                           <li>Fort√¶l din l√¶ge, hvis du har en sygdomshistorie med gentagne infektioner eller andre tilf√¶lde, der for√∏ger risikoen for infektioner. </li>
                        </ul>
                        <div class="paragraph">
                           <b>
                              <br/>Hepatitis B-virus</b>
                        </div>
                        <ul>
                           <li>Fort√¶l din l√¶ge, hvis du er b√¶rer af hepatitis B-virus (HBV), hvis du har aktiv HBV-infektion eller, hvis du tror, du kan have risiko for at f√• HBV. L√¶gen vil teste dig for HBV. Adalimumab kan reaktivere HBV-infektion hos mennesker, der b√¶rer denne virus. I sj√¶ldne tilf√¶lde, specielt hvis du tager anden medicin, der undertrykker immunsystemet, kan reaktivering af HBV-infektion blive livstruende. </li>
                        </ul>
                        <div class="paragraph">
                           <br/>
                           <b>Over 65 √•r</b>
                        </div>
                        <ul>
                           <li>Hvis du er over 65 √•r, kan du v√¶re mere modtagelig for infektioner, mens du tager Hyrimoz. Du og din l√¶ge b√∏r v√¶re s√¶rligt opm√¶rksomme p√• tegn p√• infektion mens du er i behandling med Hyrimoz. Det er vigtigt, at du fort√¶ller l√¶gen, hvis du f√•r symptomer p√• infektion s√•som feber, s√•r, tr√¶thedsfornemmelse eller problemer med t√¶nderne. </li>
                        </ul>
                        <div class="paragraph">
                           <b>
                              <br/>Operation eller tandbehandling</b>
                        </div>
                        <ul>
                           <li>Hvis du skal opereres eller have tandbehandling, skal du fort√¶lle din l√¶ge, at du tager Hyrimoz. Din l√¶ge kan anbefale midlertidig afbrydelse af Hyrimoz. </li>
                        </ul>
                        <div class="paragraph">
                           <b>
                              <br/>Demyeliniserende sygdom</b>
                        </div>
                        <ul>
                           <li>Hvis du har eller udvikler demyeliniserende sygdom (en sygdom, der p√•virker det isolerende lag rundt om nerverne som dissemineret sklerose) vil din l√¶ge afg√∏re, om du skal have eller forts√¶tte med at f√• Hyrimoz. Fort√¶l straks din l√¶ge, hvis du f√•r √¶ndringer i dit syn, svaghed i arme eller ben eller f√∏lelsesl√∏shed eller en snurrende fornemmelse et sted i kroppen. </li>
                        </ul>
                        <div class="paragraph">
                           <b>
                              <br/>Vacciner</b>
                        </div>
                        <ul>
                           <li>Visse vacciner indeholder levende men svage former for sygdomsfremkaldende bakterier eller vira og infektioner og b√∏r ikke gives under Hyrimoz-behandling i tilf√¶lde af, at de giver infektioner. Tal venligst med l√¶gen, f√∏r du f√•r nogen form for vaccine. Det anbefales, at b√∏rn s√• vidt som muligt f√•r alle vaccinationer i overensstemmelse med g√¶ldende retningslinjer for deres alder, f√∏r behandlingen med Hyrimoz indledes. Hvis du har f√•et Hyrimoz, mens du var gravid, kan dit sp√¶dbarn have en h√∏jere risiko for at f√• en infektion i op til ca. fem m√•neder efter din sidste dosis under graviditeten. Det er vigtigt, at du fort√¶ller barnets l√¶ge og andre sundhedspersoner, at du fik Hyrimoz under graviditeten, s√• de kan beslutte, hvorn√•r dit sp√¶dbarn b√∏r vaccineres. </li>
                        </ul>
                        <div class="paragraph">
                           <b>
                              <br/>Hjertesvigt</b>
                        </div>
                        <ul>
                           <li>Det er vigtigt at informere l√¶gen, hvis du har eller har haft en alvorlig hjertesygdom. Hvis du har lettere hjertesvigt og bliver behandlet med Hyrimoz, skal status for dit hjertesvigt f√∏lges n√∏je af din l√¶ge. Hvis du udvikler nye eller f√•r forv√¶rrede symptomer p√• hjertesvigt (f.eks. stak√•ndethed eller h√¶vede f√∏dder), skal du kontakte din l√¶ge √∏jeblikkeligt. </li>
                        </ul>
                        <div class="paragraph">
                           <b>
                              <br/>Feber, bl√• m√¶rker, bl√∏dning eller bleghed</b>
                        </div>
                        <ul>
                           <li>Hos nogle patienter vil kroppen ikke producere tilstr√¶kkeligt af de blodlegemer, som hj√¶lper kroppen med at bek√¶mpe infektioner eller hj√¶lper med at stoppe bl√∏dninger. Hvis du f√•r feber, som ikke vil forsvinde, bl√• m√¶rker eller bl√∏der meget let eller er meget bleg, skal du omg√•ende henvende dig til din l√¶ge. Din l√¶ge kan eventuelt beslutte at afbryde behandlingen. </li>
                        </ul>
                        <div class="paragraph">
                           <b>
                              <br/>Kr√¶ft</b>
                        </div>
                        <ul>
                           <li>Der er set meget sj√¶ldne tilf√¶lde af visse kr√¶fttyper hos patienter, som tager adalimumab eller andre TNFŒ±-h√¶mmere. Patienter med mere alvorlig reumatoid artrit, som har haft sygdommen i lang tid, kan have √∏get risiko i forhold til gennemsnittet for at f√• lymfomer og leuk√¶mi (kr√¶fttyper, som p√•virker blodlegemer og knoglemarv). N√•r du tager Hyrimoz, kan risikoen for at f√• et lymfom, leuk√¶mi eller andre former for kr√¶ft √∏ges. I sj√¶ldne tilf√¶lde er der set en alvorlig type af lymfom hos patienter, som tog adalimumab. Nogle af disse patienter blev ogs√• behandlet med l√¶gemidlerne azathioprin eller mercaptopurin. Fort√¶l din l√¶ge, hvis du f√•r l√¶gemidlerne azathioprin eller mercaptopurin sammen med Hyrimoz. </li>
                           <li>Derudover er der set tilf√¶lde af ikke-melanom hudkr√¶ft hos patienter, der tager adalimumab. Hvis der kommer nye omr√•der med beskadiget hud under eller efter behandlingen, eller hvis de nuv√¶rende beskadigede omr√•der forandrer sig, skal du fort√¶lle det til din l√¶ge. </li>
                           <li>Der har v√¶ret tilf√¶lde af kr√¶ft, der er forskellig fra lymfom hos patienter med en specifik lungesygdom kaldet kronisk obstruktiv lungesygdom (KOL), der var i behandling med en anden TNFŒ±-h√¶mmer. Hvis du har KOL, eller ryger meget, b√∏r du diskutere med din l√¶ge, om behandling med en TNFŒ±-h√¶mmer er passende for dig. </li>
                        </ul>
                        <div class="paragraph">
                           <b>
                              <br/>Autoimmune sygdomme</b>
                        </div>
                        <ul>
                           <li>I sj√¶ldne tilf√¶lde kan behandling med Hyrimoz resultere i lupus-lignende syndrom. Fort√¶l din l√¶ge hvis der opst√•r symptomer s√•som vedvarende uforklarligt udsl√¶t, feber, ledsmerter eller tr√¶thed. </li>
                        </ul>
                        <h3>  B√∏rn og unge  </h3>
                        <ul>
                           <li>Giv ikke Hyrimoz til b√∏rn under 2 √•r med polyartikul√¶r juvenil idiopatisk artrit. </li>
                           <li>Giv ikke Hyrimoz til b√∏rn under 4 √•r med p√¶diatrisk plaque-psoriasis eller p√¶diatrisk colitis ulcerosa</li>
                           <li>Giv ikke Hyrimoz til b√∏rn under 6 √•r med p√¶diatrisk Crohns sygdom</li>
                           <li>Brug ikke 40 mg fyldt pen, hvis det anbefales at bruge andre doser end 40 mg</li>
                        </ul>
                        <h3>  Brug af anden medicin sammen med Hyrimoz  </h3>
                        <div class="paragraph">Fort√¶l altid l√¶gen eller apotekspersonalet, hvis du bruger anden medicin for nylig har brugt anden medicin eller planl√¶gger at bruge anden medicin.</div>
                        <div class="paragraph">
                           <br/>Hyrimoz kan anvendes sammen med methotrexat eller visse sygdomsmodificerende antireumatiske l√¶gemidler (sulfasalazin, hydroxychloroquin, leflunomid og guldpr√¶parater til injektion), kortikosteroider eller smertemedicin, herunder non-steroide anti-inflammatoriske l√¶gemidler (NSAIDs).</div>
                        <div class="paragraph">
                           <br/>P√• grund af √∏get risiko for alvorlig infektion, m√• du ikke tage Hyrimoz sammen med medicin, der indeholder de aktive stoffer anakinra eller abatacept. Det anbefales ikke at kombinere adalimumab s√•vel som andre TNF-antagonister og anakira eller abatacept, grundet den mulige √∏gede risiko for infektion som for eksempel alvorlige infektioner og andre mulige farmakologiske interaktioner (l√¶gemidlers p√•virkning p√• hinanden). Hvis du har sp√∏rgsm√•l, skal du tale med din l√¶ge.</div>
                        <h3>  Graviditet og amning  </h3>
                        <ul>
                           <li>Du b√∏r overveje brugen af passende pr√¶vention for at forhindre graviditet og forts√¶tte brugen mindst 5 m√•neder efter den sidste behandling med Hyrimoz. </li>
                           <li>Hvis du er gravid, har mistanke, om at du er gravid, eller planl√¶gger at blive gravid, skal du sp√∏rge din l√¶ge til r√•ds, f√∏r du tager dette l√¶gemiddel. </li>
                           <li>Hyrimoz b√∏r kun anvendes under graviditet, hvis det er tydeligvis er n√∏dvendigt. </li>
                           <li>Der var if√∏lge et graviditetsstudie ikke h√∏jere risiko for misdannelser, n√•r moderen havde f√•et adalimumab under graviditeten, ved sammenligning med m√∏dre med samme sygdom, som ikke havde f√•et adalimumab. </li>
                           <li>Hyrimoz kan anvendes under amning. </li>
                           <li>Hvis du f√•r Hyrimoz, mens du er gravid, kan dit sp√¶dbarn have en h√∏jere risiko for at f√• en infektion. </li>
                           <li>Det er vigtigt, at du fort√¶ller barnets l√¶ge og andre sundhedspersoner om din brug af Hyrimoz under graviditeten, f√∏r dit barn f√•r nogen vaccinationer. For mere information om vacciner, se afsnittet &quot;Advarsler og forsigtighedsregler&quot;. </li>
                        </ul>
                        <h3>  Trafik- og arbejdssikkerhed  </h3>
                        <div class="paragraph">Hyrimoz kan i mindre grad p√•virke din evne til at f√¶rdes i trafikken, cykle eller betjene maskiner. Du kan f√• synsforstyrrelser og en fornemmelse af, at rummet drejer rundt (svimmelhed), efter du har taget Hyrimoz.</div>
                        <h3>  Hyrimoz indeholder natrium  </h3>
                        <div class="paragraph">Denne medicin indeholder mindre end 1 mmol natrium (23 mg) pr. 0,8 ml dosis, dvs. den er i det v√¶sentlige natriumfri.</div>
                     </div>
            </text>
          </section>
          <section>
            <title value="3. S√•dan skal du tage Hyrimoz"/>
            <code>
              <coding>
                <system value="https://spor.ema.europa.eu/v1/lists/200000029659/terms/"/>
                <code value="200000029905"/>
              </coding>
            </code>
            <text>
              <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                        <a name="Section3"/>
                        <div>¬†</div>
                        <h2>3. S√•dan skal du tage Hyrimoz</h2>
                        <div class="paragraph">Tag altid l√¶gemidlet n√∏jagtig efter l√¶gens anvisning. Er du i tvivl, s√• sp√∏rg l√¶gen eller apotekspersonalet.</div>
                        <div class="paragraph">
                           <br/>Hyrimoz f√•s som en 40 mg pen samt som 20 mg og 40 mg fyldte injektionsspr√∏jter, s√• patienter kan administrere en fuld dosis p√• 20 mg eller 40 mg</div>
                        <div class="paragraph">¬†</div>
                        <table border="1" cellpadding="4" cellspacing="0" width="100%" style="border-collapse:collapse;">
                           <colgroup/>
                           <tr>
                              <td colspan="3" style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Reumatoid artrit, psoriasisartrit, ankyloserende spondylitis eller aksial spondyloartritis uden radiografiske tegn p√• ankyloserende spondylitis</b>
                                 </div>
                              </td>
                           </tr>
                           <tr>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Alder og kropsv√¶gt</b>
                                 </div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Hvor meget og hvor ofte skal det tages?</b>
                                 </div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Bem√¶rkninger</b>
                                 </div>
                              </td>
                           </tr>
                           <tr>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">Voksne</div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">40 mg hver anden uge som en enkelt dosis</div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">Ved reumatoid artrit forts√¶ttes methotrexat mens Hyrimoz bruges. Hvis din l√¶ge beslutter, at methotrexat ikke er passende, kan Hyrimoz gives alene.</div>
                                 <div class="paragraph">
                                    <br/>Hvis du har reumatoid artrit, og du ikke f√•r methotrexat sammen med din Hyrimoz-behandling, kan l√¶gen beslutte at give dig 40 mg Hyrimoz hver uge eller 80 mg hver anden uge.</div>
                              </td>
                           </tr>
                        </table>
                        <div class="paragraph">¬†</div>
                        <table border="1" cellpadding="4" cellspacing="0" width="100%" style="border-collapse:collapse;">
                           <colgroup/>
                           <tr>
                              <td colspan="3" style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Polyartikul√¶r juvenil idiopatisk artrit</b>
                                 </div>
                              </td>
                           </tr>
                           <tr>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Alder og kropsv√¶gt</b>
                                 </div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Hvor meget og hvor ofte skal det tages?</b>
                                 </div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Bem√¶rkninger</b>
                                 </div>
                              </td>
                           </tr>
                           <tr>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">B√∏rn, unge og voksne fra 2 √•r, som vejer 30 kg eller mere</div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">40 mg hver anden uge</div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">Ikke relevant</div>
                              </td>
                           </tr>
                           <tr>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">B√∏rn, unge og voksne fra 2 √•r, som vejer 10 kg til under 30 kg</div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">20 mg hver anden uge</div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">Ikke relevant</div>
                              </td>
                           </tr>
                        </table>
                        <div class="paragraph">¬†</div>
                        <table border="1" cellpadding="4" cellspacing="0" width="100%" style="border-collapse:collapse;">
                           <colgroup/>
                           <tr>
                              <td colspan="3" style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Entesopatirelateret artrit</b>
                                 </div>
                              </td>
                           </tr>
                           <tr>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Alder og kropsv√¶gt</b>
                                 </div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Hvor meget og hvor ofte skal det tages?</b>
                                 </div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Bem√¶rkninger</b>
                                 </div>
                              </td>
                           </tr>
                           <tr>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">B√∏rn, unge og voksne fra 6 √•r, som vejer 30 kg eller mere</div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">40 mg hver anden uge</div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">Ikke relevant</div>
                              </td>
                           </tr>
                           <tr>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">B√∏rn, unge og voksne fra 6 √•r, som vejer 15 kg til under 30 kg</div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">20 mg hver anden uge</div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">Ikke relevant</div>
                              </td>
                           </tr>
                        </table>
                        <div class="paragraph">¬†</div>
                        <table border="1" cellpadding="4" cellspacing="0" width="100%" style="border-collapse:collapse;">
                           <colgroup/>
                           <tr>
                              <td colspan="3" style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Psoriasis</b>
                                 </div>
                              </td>
                           </tr>
                           <tr>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Alder og kropsv√¶gt</b>
                                 </div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Hvor meget og hvor ofte skal det tages?</b>
                                 </div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Bem√¶rkninger</b>
                                 </div>
                              </td>
                           </tr>
                           <tr>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">Voksne</div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">F√∏rste dosis er 80 mg (som to 40 mg injektioner p√• √©n dag), efterfulgt af 40 mg givet hver anden uge med begyndelse √©n uge efter den f√∏rste dosis.</div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">Du skal forts√¶tte med at injicere Hyrimoz s√• l√¶nge, som din l√¶ge har fortalt dig. Hvis denne dosis ikke virker godt nok, kan din l√¶ge √∏ge dosis til 40 mg hver uge eller 80 mg hver anden uge.</div>
                              </td>
                           </tr>
                        </table>
                        <div class="paragraph">¬†</div>
                        <table border="1" cellpadding="4" cellspacing="0" width="100%" style="border-collapse:collapse;">
                           <colgroup/>
                           <tr>
                              <td colspan="3" style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Plaque-psoriasis</b>
                                 </div>
                              </td>
                           </tr>
                           <tr>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Alder og kropsv√¶gt</b>
                                 </div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Hvor meget og hvor ofte skal det tages?</b>
                                 </div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Bem√¶rkninger</b>
                                 </div>
                              </td>
                           </tr>
                           <tr>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">B√∏rn og unge fra 4 til 17 √•r, som vejer 30 kg eller mere</div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">F√∏rste dosis er 40 mg, efterfulgt af 40 mg √©n uge senere.<br/>
                                    <br/>Derefter er den s√¶dvanlige dosis 40 mg hver anden uge.</div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">Ikke relevant</div>
                              </td>
                           </tr>
                           <tr>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">B√∏rn og unge fra 4 til 17 √•r, som vejer 15 kg til under 30 kg</div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">F√∏rste dosis er 20 mg, efterfulgt af 20 mg √©n uge senere.<br/>
                                    <br/>Derefter er den s√¶dvanlige dosis 20 mg hver anden uge.</div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">Ikke relevant</div>
                              </td>
                           </tr>
                        </table>
                        <div class="paragraph">¬†</div>
                        <table border="1" cellpadding="4" cellspacing="0" width="100%" style="border-collapse:collapse;">
                           <colgroup/>
                           <tr>
                              <td colspan="3" style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Hidradenitis suppurativa</b>
                                 </div>
                              </td>
                           </tr>
                           <tr>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Alder og kropsv√¶gt</b>
                                 </div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Hvor meget og hvor ofte skal det tages?</b>
                                 </div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Bem√¶rkninger</b>
                                 </div>
                              </td>
                           </tr>
                           <tr>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">Voksne</div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">F√∏rste dosis er 160 mg (som fire 40 mg injektioner p√• √©n dag eller to 40 mg injektioner pr. dag i to fortl√∏bende dage), efterfulgt af en 80 mg dosis (som to 40 mg injektioner p√• samme dag) to uger senere.</div>
                                 <div class="paragraph">
                                    <br/>Efter yderligere to uger forts√¶ttes med en dosis p√• 40 mg hver uge eller 80 mg hver anden uge som ordineret af din l√¶ge.</div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">Det anbefales, at du dagligt bruger et antiseptisk vaskemiddel p√• de ber√∏rte omr√•der.</div>
                              </td>
                           </tr>
                           <tr>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">Unge fra 12 til 17 √•r, der vejer 30 kg eller mere</div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">F√∏rste dosis er 80 mg (som to 40 mg injektioner p√• √©n dag), efterfulgt af 40 mg hver anden uge med begyndelse √©n uge senere.</div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">Hvis denne dosis ikke virker godt nok, kan din l√¶ge √∏ge dosis til 40 mg hver uge eller 80 mg hver anden uge.</div>
                                 <div class="paragraph">
                                    <br/>Det anbefales, at du dagligt bruger et antiseptisk vaskemiddel p√• de ber√∏rte omr√•der.</div>
                              </td>
                           </tr>
                        </table>
                        <div class="paragraph">¬†</div>
                        <table border="1" cellpadding="4" cellspacing="0" width="100%" style="border-collapse:collapse;">
                           <colgroup/>
                           <tr>
                              <td colspan="3" style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Crohns sygdom</b>
                                 </div>
                              </td>
                           </tr>
                           <tr>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Alder og kropsv√¶gt</b>
                                 </div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Hvor meget og hvor ofte skal det tages?</b>
                                 </div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Bem√¶rkninger</b>
                                 </div>
                              </td>
                           </tr>
                           <tr>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">Voksne</div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">F√∏rste dosis er 80 mg (som to 40 mg injektioner p√• √©n dag), efterfulgt af 40 mg hver anden uge med begyndelse to uger senere.</div>
                                 <div class="paragraph">
                                    <br/>Hvis der er brug for et hurtigere respons, kan l√¶gen ordinere en f√∏rste dosis p√• 160 mg (som fire 40 mg injektioner p√• √©n dag eller to 40 mg injektioner pr. dag i to fortl√∏bende dage), efterfulgt af 80 mg (som to 40 mg injektioner p√• √©n dag) to uger senere.</div>
                                 <div class="paragraph">
                                    <br/>Derefter er den s√¶dvanlige dosis 40 mg hver anden uge.</div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">Hvis denne dosis ikke virker godt nok, kan din l√¶ge √∏ge dosis til 40 mg hver uge eller 80 mg hver anden uge.</div>
                              </td>
                           </tr>
                        </table>
                        <div class="paragraph">¬†</div>
                        <table border="1" cellpadding="4" cellspacing="0" width="100%" style="border-collapse:collapse;">
                           <colgroup/>
                           <tr>
                              <td colspan="3" style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Crohns sygdom hos b√∏rn</b>
                                 </div>
                              </td>
                           </tr>
                           <tr>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Alder og kropsv√¶gt</b>
                                 </div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Hvor meget og hvor ofte skal det tages?</b>
                                 </div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Bem√¶rkninger</b>
                                 </div>
                              </td>
                           </tr>
                           <tr>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">B√∏rn og unge fra 6 til 17 √•r, som vejer 40 kg eller mere</div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">F√∏rste dosis er 80 mg (som to 40 mg injektioner p√• √©n dag), efterfulgt af 40 mg hver anden uge med begyndelse to uger senere.</div>
                                 <div class="paragraph">
                                    <br/>Hvis der er brug for et hurtigere respons, kan l√¶gen ordinere en f√∏rste dosis p√• 160 mg (som fire 40 mg injektioner p√• √©n dag eller to 40 mg injektioner pr. dag i to fortl√∏bende dage), efterfulgt af 80 mg (som to 40 mg injektioner p√• √©n dag) to uger senere.</div>
                                 <div class="paragraph">
                                    <br/>Derefter er den s√¶dvanlige dosis 40 mg hver anden uge.</div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">Hvis denne dosis ikke virker godt nok, kan dit barns l√¶ge √∏ge dosis til 40 mg hver uge eller 80 mg hver anden uge.</div>
                              </td>
                           </tr>
                           <tr>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">B√∏rn og unge fra 6 til 17 √•r, som vejer under 40 kg</div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">F√∏rste dosis er 40 mg, efterfulgt af 20 mg hver anden uge med begyndelse to uger senere.</div>
                                 <div class="paragraph">
                                    <br/>Hvis der er brug for et hurtigere respons, kan l√¶gen ordinere en f√∏rste dosis p√• 80 mg (som to 40 mg injektioner p√• √©n dag), efterfulgt af 40 mg to uger senere.</div>
                                 <div class="paragraph">
                                    <br/>Derefter er den s√¶dvanlige dosis 20 mg hver anden uge.</div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">Hvis denne dosis ikke virker godt nok, kan dit barns l√¶ge √∏ge hyppigheden af dosis til 20 mg hver uge.</div>
                              </td>
                           </tr>
                        </table>
                        <div class="paragraph">¬†</div>
                        <table border="1" cellpadding="4" cellspacing="0" width="100%" style="border-collapse:collapse;">
                           <colgroup/>
                           <tr>
                              <td colspan="3" style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Colitis ulcerosa</b>
                                 </div>
                              </td>
                           </tr>
                           <tr>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Alder og kropsv√¶gt</b>
                                 </div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Hvor meget og hvor ofte skal det tages?</b>
                                 </div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Bem√¶rkninger</b>
                                 </div>
                              </td>
                           </tr>
                           <tr>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">Voksne</div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">F√∏rste dosis er 160 mg (som fire 40 mg injektioner p√• √©n dag eller som to 40 mg injektioner pr. dag i to fortl√∏bende dage), efterfulgt af 80 mg (som to 40 mg injektioner p√• √©n dag) to uger senere.</div>
                                 <div class="paragraph">
                                    <br/>Derefter er den s√¶dvanlige dosis 40 mg hver anden uge.</div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">Hvis denne dosis ikke virker godt nok, kan din l√¶ge √∏ge dosis til 40 mg hver uge eller 80 mg hver anden uge.</div>
                              </td>
                           </tr>
                        </table>
                        <div class="paragraph">¬†</div>
                        <table border="1" cellpadding="4" cellspacing="0" width="100%" style="border-collapse:collapse;">
                           <colgroup/>
                           <tr>
                              <td colspan="3" style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Ikke-infekti√∏s uveitis</b>
                                 </div>
                              </td>
                           </tr>
                           <tr>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Alder og kropsv√¶gt</b>
                                 </div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Hvor meget og hvor ofte skal det tages?</b>
                                 </div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">
                                    <b>Bem√¶rkninger</b>
                                 </div>
                              </td>
                           </tr>
                           <tr>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">Voksne</div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">F√∏rste dosis er 80 mg (som to 40 mg injektioner), efterfulgt af 40 mg hver anden uge med begyndelse √©n uge efter den f√∏rste dosis.</div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">Ved ikke-infekti√∏s uveitis kan behandling med kortikosteroider eller anden medicin, der p√•virker immunsystemet, forts√¶ttes under behandling med Hyrimoz. Hyrimoz kan ogs√• gives alene.</div>
                                 <div class="paragraph">
                                    <br/>Du skal forts√¶tte med at injicere Hyrimoz s√• l√¶nge, som din l√¶ge har fortalt dig.</div>
                              </td>
                           </tr>
                           <tr>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">B√∏rn og unge fra 2 √•r, som vejer 30 kg eller mere</div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">40 mg hver anden uge sammen med methotrexat</div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">L√¶gen kan ogs√• ordinere en f√∏rste dosis p√• 80 mg, som kan gives √©n uge f√∏r start af den s√¶dvanlige dosis.</div>
                              </td>
                           </tr>
                           <tr>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">B√∏rn og unge fra 2 √•r, som vejer under 30 kg</div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">20 mg hver anden uge sammen med methotrexat</div>
                              </td>
                              <td style="width:33%;" valign="top" align="left">
                                 <div class="paragraph">L√¶gen kan ogs√• ordinere en f√∏rste dosis p√• 40 mg, som kan gives √©n uge f√∏r start af den s√¶dvanlige dosis.</div>
                              </td>
                           </tr>
                        </table>
                        <div class="paragraph">¬†</div>
                        <h3>  Metode og indgivelsesvej  </h3>
                        <div class="paragraph">Hyrimoz indgives ved injektion under huden (subkutan injektion).</div>
                        <div class="paragraph">
                           <br/>Detaljeret vejledning om, hvordan Hyrimoz injiceres, gives i <a href="#Section0" title="Anchor link til afsnit - punkt 7">punkt 7</a> ‚Äù<b>Brugsvejledning</b>‚Äù.</div>
                        <h3>  Hvis du har taget for meget Hyrimoz  </h3>
                        <div class="paragraph">Hvis du ved en fejltagelse injicerer Hyrimoz hyppigere end forskrevet, skal du kontakte l√¶gen eller apotekspersonalet og forklare, at du har taget mere medicin end n√∏dvendigt. Tag altid medicinens ydre karton med, ogs√• selvom den er tom.</div>
                        <h3>  Hvis du har glemt at tage Hyrimoz  </h3>
                        <div class="paragraph">Hvis du glemmer at give dig selv en injektion, skal du injicere den n√¶ste dosis af Hyrimoz, s√• snart du kommer i tanke om det. Forts√¶t dern√¶st med at injicere n√¶ste dosis som planlagt p√• den oprindeligt fastlagte dag, som om du ikke havde glemt en dosis.</div>
                        <h3>  Hvis du holder op med at tage Hyrimoz  </h3>
                        <div class="paragraph">Beslutningen om at stoppe med at bruge Hyrimoz skal diskuteres med din l√¶ge. Dine symptomer kan komme igen efter oph√∏r af behandlingen.</div>
                        <div class="paragraph">
                           <br/>Sp√∏rg l√¶gen eller apotekspersonalet, hvis der er noget, du er i tvivl om.</div>
                     </div>
            </text>
          </section>
          <section>
            <title value="4. Bivirkninger"/>
            <code>
              <coding>
                <system value="https://spor.ema.europa.eu/v1/lists/200000029659/terms/"/>
                <code value="200000029910"/>
              </coding>
            </code>
            <text>
              <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                        <a name="Section4"/>
                        <div>¬†</div>
                        <h2>4. Bivirkninger</h2>
                        <div class="paragraph">Dette l√¶gemiddel kan som alle andre l√¶gemidler give bivirkninger, men ikke alle f√•r bivirkninger. De fleste bivirkninger er af let til moderat grad. Der kan dog forekomme mere alvorlige bivirkninger, som kr√¶ver behandling. Bivirkninger kan forekomme op til 4 m√•neder eller mere efter den sidste</div>
                        <div class="paragraph">Hyrimoz-injektion.</div>
                        <div class="paragraph">
                           <br/>
                           <b>S√∏g straks l√¶gehj√¶lp</b>, hvis du bem√¶rker f√∏lgende tegn p√• en allergisk reaktion eller hjertesvigt:</div>
                        <ul>
                           <li>alvorligt udsl√¶t eller n√¶ldefeber </li>
                           <li>h√¶velser i ansigt, h√¶nder eller f√∏dder </li>
                           <li>besv√¶r med at tr√¶kke vejret eller synke </li>
                           <li>stak√•ndethed ved fysisk anstrengelse eller n√•r du ligger ned, eller h√¶vede f√∏dder. </li>
                        </ul>
                        <div class="paragraph">
                           <br/>
                           <b>Kontakt l√¶gen s√• hurtigt som muligt</b>, hvis du bem√¶rker et eller flere af f√∏lgende symptomer:</div>
                        <ul>
                           <li>tegn og symptomer p√• infektion, s√•som feber, f√∏lelse af sygdom, s√•r, tandproblemer eller smerter ved vandladning, f√∏lelse af svaghed eller tr√¶thed eller hoste; </li>
                           <li>symptomer p√• nerveproblemer som snurren og prikken, f√∏lelsesl√∏shed, dobbeltsyn eller svaghed i arme og ben; </li>
                           <li>tegn p√• hudkr√¶ft som en bule eller √•bent s√•r, som ikke vil hele </li>
                           <li>tegn og symptomer, som kan tyde p√• blodsygdomme s√•som vedvarende feber, bl√• m√¶rker, bl√∏dning, bleghed. </li>
                        </ul>
                        <h3>  F√∏lgende bivirkninger er observeret ved brug af adalimumab:  </h3>
                        <div class="paragraph">
                           <b>Meget almindelige </b>(kan p√•virke flere end 1 ud af 10 personer)</div>
                        <ul>
                           <li>reaktioner ved injektionsstedet (herunder smerter, h√¶velse, r√∏dme eller kl√∏e) </li>
                           <li>luftvejsinfektioner (inklusive fork√∏lelse, l√∏bende n√¶se, bihulebet√¶ndelse, lungebet√¶ndelse) </li>
                           <li>hovedpine </li>
                           <li>mavesmerter </li>
                           <li>kvalme og opkastning </li>
                           <li>udsl√¶t </li>
                           <li>muskelsmerter. </li>
                        </ul>
                        <div class="paragraph">
                           <br/>
                           <b>Almindelige </b>(kan p√•virke op til 1 ud af 10 personer)</div>
                        <ul>
                           <li>alvorlige infektioner (inklusive blodforgiftning og influenza) </li>
                           <li>tarminfektioner (inklusive bet√¶ndelse i mave og tarm) </li>
                           <li>hudinfektioner (inklusive bindev√¶vsbet√¶ndelse og helvedessild) </li>
                           <li>√∏reinfektioner </li>
                           <li>infektioner i munden (inklusive tandinfektioner og fork√∏lelsess√•r) </li>
                           <li>infektioner i k√∏nsvejene </li>
                           <li>urinvejsinfektion </li>
                           <li>svampeinfektioner </li>
                           <li>ledinfektioner </li>
                           <li>godartede svulster </li>
                           <li>hudkr√¶ft </li>
                           <li>allergiske reaktioner (inklusive s√¶sonbestemt allergi) </li>
                           <li>dehydrering (v√¶skemangel) </li>
                           <li>hum√∏rsvingninger (inklusive depression) </li>
                           <li>angst </li>
                           <li>s√∏vnbesv√¶r </li>
                           <li>f√∏lelsesforstyrrelser s√•som snurren, prikken eller f√∏lelsesl√∏shed </li>
                           <li>migr√¶ne </li>
                           <li>symptomer p√• nerverodskompression (inklusive smerter i den nederste del af ryggen og bensmerter) </li>
                           <li>synsforstyrrelser </li>
                           <li>bet√¶ndelse i √∏jet </li>
                           <li>bet√¶ndelse i √∏jenl√•get og h√¶vede √∏jne </li>
                           <li>vertigo (fornemmelse af at snurre rundt) </li>
                           <li>fornemmelse af hurtige hjerteslag </li>
                           <li>h√∏jt blodtryk </li>
                           <li>r√∏dme </li>
                           <li>blodansamling </li>
                           <li>hoste </li>
                           <li>astma </li>
                           <li>kort√•ndethed </li>
                           <li>bl√∏dning i mave-tarm-kanalen </li>
                           <li>sure opst√∏d (ford√∏jelsesbesv√¶r, oppustethed, halsbrand) </li>
                           <li>syrereflukssygdom </li>
                           <li>Sj√∏grens syndrom (inklusive t√∏rre √∏jne og t√∏r mund) </li>
                           <li>kl√∏e </li>
                           <li>kl√∏ende udsl√¶t </li>
                           <li>bl√• m√¶rker </li>
                           <li>inflammation i huden (s√•som eksem) </li>
                           <li>fingernegle og t√•negle kn√¶kker </li>
                           <li>√∏get svedtendens </li>
                           <li>h√•rtab </li>
                           <li>nye udbrud eller forv√¶rring af psoriasis </li>
                           <li>muskelspasmer </li>
                           <li>blod i urinen </li>
                           <li>nyreproblemer </li>
                           <li>brystsmerter </li>
                           <li>√∏dem (v√¶skeophobning i kroppen, som f√•r det p√•virkede v√¶v til at h√¶ve) </li>
                           <li>feber </li>
                           <li>nedsat antal blodplader med for√∏get risiko for bl√∏dning eller bl√• m√¶rker </li>
                           <li>forringet s√•rheling. </li>
                        </ul>
                        <div class="paragraph">
                           <br/>
                           <b>Ikke almindelig </b>(kan p√•virke op til 1 ud af 100 personer)</div>
                        <ul>
                           <li>us√¶dvanlige infektioner (som inkluderer tuberkulose og andre infektioner), som forekommer, n√•r modstandskraften mod sygdom er nedsat) </li>
                           <li>neurologiske infektioner (inklusive viral meningitis) </li>
                           <li>√∏jeninfektioner </li>
                           <li>bakterieinfektioner </li>
                           <li>irritation og infektion i tyktarmen (diverticulitis) </li>
                           <li>kr√¶ft inklusive kr√¶ft, der rammer lymfesystemet (lymfom) og moderm√¶rkekr√¶ft </li>
                           <li>sygdomme i immunsystemet, som kan p√•virke lungerne, huden og lymfeknuderne (viser sig oftest som en sygdom, der kaldes sarkoidose) </li>
                           <li>vaskulitis (bet√¶ndelse i blodkar) </li>
                           <li>rysten </li>
                           <li>neuropati (nerveskade) </li>
                           <li>slagtilf√¶lde </li>
                           <li>dobbeltsyn </li>
                           <li>h√∏retab, summen for √∏rerne </li>
                           <li>fornemmelse af uregelm√¶ssige hjerteslag s√•som oversprungne slag </li>
                           <li>hjerteproblemer, som kan for√•rsage kort√•ndethed og h√¶vede ankler </li>
                           <li>hjertetilf√¶lde </li>
                           <li>s√¶klignende udposning p√• v√¶ggen af en st√∏rre puls√•re (aneurisme), bet√¶ndelse og blodprop i en blod√•re, tilstopning af et blodkar </li>
                           <li>lungesygdom, som for√•rsager kort√•ndethed (inklusive inflammation) </li>
                           <li>blodprop i lungerne (lungeemboli) </li>
                           <li>unormal ophobning af v√¶ske mellem lungehinderne (pleuraeffusion) </li>
                           <li>inflammation i bugspytkirtlen, som kan give alvorlige smerter i maven og ryggen </li>
                           <li>synkebesv√¶r </li>
                           <li>h√¶velse i ansigtet </li>
                           <li>inflammation i galdebl√¶ren, galdesten </li>
                           <li>fedtlever (ophobning af fedt i levercellerne) </li>
                           <li>nattesved </li>
                           <li>ar </li>
                           <li>unormal muskelnedbrydning </li>
                           <li>systemisk lupus erythematosus (en immunforstyrrelse, der indbefatter bet√¶ndelse i huden, hjertet, lungerne, leddene og andre organsystemer) </li>
                           <li>s√∏vnafbrydelser </li>
                           <li>impotens </li>
                           <li>inflammationer. </li>
                        </ul>
                        <div class="paragraph">
                           <br/>
                           <b>Sj√¶ldne </b>(kan p√•virke op til 1 ud af 1.000 personer)</div>
                        <ul>
                           <li>leuk√¶mi (kr√¶ft, som p√•virker blod og knoglemarv) </li>
                           <li>alvorlig allergisk reaktion med shock </li>
                           <li>dissemineret sklerose </li>
                           <li>nerveforstyrrelser (s√•som inflammation (bet√¶ndelse) i synsnerven og Guillain-Barr√© syndrom, en sygdom, som kan for√•rsage muskelsvaghed, unormal f√∏lesans, prikken i arme og overkrop) </li>
                           <li>hjertestop </li>
                           <li>lungefibrose (dannelse af arv√¶v i lungerne) </li>
                           <li>perforering af tarmen (hul i tarmv√¶ggen) </li>
                           <li>hepatit (leverbet√¶ndelse) </li>
                           <li>genopblussen af hepatitis B-infektion </li>
                           <li>autoimmun hepatit (leverbet√¶ndelse for√•rsaget af kroppens eget immunsystem) </li>
                           <li>inflammation/bet√¶ndelse i hudens blodkar (kutan vaskulitis) </li>
                           <li>Stevens-Johnsons syndrom (livstruende reaktion med influenza-lignende symptomer og udsl√¶t med bl√¶rer) </li>
                           <li>√∏dem (h√¶velse) i ansigtet forbundet med allergiske reaktioner </li>
                           <li>bet√¶ndelseslignende hududsl√¶t (erythema multiforme) </li>
                           <li>lupus-lignende syndrom </li>
                           <li>angio√∏dem (lokal h√¶velse af huden) </li>
                           <li>lichenoid hudreaktion (kl√∏ende r√∏dligt-lilla hududsl√¶t). </li>
                        </ul>
                        <div class="paragraph">
                           <br/>
                           <b>Ikke kendt </b>(hyppigheden kan ikke estimeres ud fra forh√•ndenv√¶rende data)</div>
                        <ul>
                           <li>hepatosplenisk T-cellelymfom (en sj√¶lden form for blodkr√¶ft, som ofte er d√∏delig) </li>
                           <li>Merkelcellekarcinom (en type hudkr√¶ft) </li>
                           <li>Kaposis sarkom, en sj√¶lden type kr√¶ft, der er forbundet med infektion med humant herpesvirus 8. Kaposis sarkom forekommer oftest som lilla l√¶sioner p√• huden </li>
                           <li>leversvigt </li>
                           <li>forv√¶rring af en tilstand, som kaldes dermatomyositis (ses som hududsl√¶t ledsaget af muskelsvaghed) </li>
                           <li>v√¶gtfor√∏gelse (for de fleste patienters vedkommende var v√¶gtfor√∏gelsen lille). </li>
                        </ul>
                        <div class="paragraph">
                           <br/>Nogle bivirkninger, som er set med adalimumab har ikke symptomer og kan kun opdages ved blodpr√∏ver. Disse inkluderer:</div>
                        <div class="paragraph">
                           <br/>
                           <b>Meget almindelige </b>(kan p√•virke flere end 1 ud af 10 personer)</div>
                        <ul>
                           <li>nedsat antal hvide blodlegemer </li>
                           <li>nedsat antal r√∏de blodlegemer </li>
                           <li>forh√∏jede lipider i blodet </li>
                           <li>forh√∏jede leverenzymer. </li>
                        </ul>
                        <div class="paragraph">
                           <br/>
                           <b>Almindelige </b>(kan p√•virke op til 1 ud af 10 personer)</div>
                        <ul>
                           <li>forh√∏jet antal hvide blodlegemer </li>
                           <li>nedsat antal blodplader </li>
                           <li>forh√∏jet urinsyre i blodet </li>
                           <li>unormale blodm√•linger af natrium </li>
                           <li>lave blodm√•linger af calcium </li>
                           <li>lave blodm√•linger af fosfat </li>
                           <li>h√∏jt blodsukker </li>
                           <li>h√∏je blodm√•linger af lactatdehydrogenase </li>
                           <li>tilstedev√¶relse af autoantistoffer i blodet </li>
                           <li>lavt kalium i blodet. </li>
                        </ul>
                        <div class="paragraph">
                           <br/>
                           <b>Ikke almindelige </b>(kan p√•virke op til 1 ud af 100 personer):</div>
                        <ul>
                           <li>forh√∏jede bilirubinm√•linger (leverblodtest) </li>
                        </ul>
                        <div class="paragraph">
                           <br/>
                           <b>Sj√¶ldne </b>(kan p√•virke op til 1 ud af 1.000 personer):</div>
                        <ul>
                           <li>nedsat antal hvide blodlegemer, r√∏de blodlegemer og blodplader. </li>
                        </ul>
                        <h3>  Indberetning af bivirkninger  </h3>
                        <div class="paragraph">Hvis du oplever bivirkninger, b√∏r du tale med din l√¶ge eller apotekspersonalet. Dette g√¶lder ogs√• mulige bivirkninger, som ikke er medtaget i denne indl√¶gsseddel.</div>
                        <div class="paragraph">
                           <br/>Du eller dine p√•r√∏rende kan ogs√• indberette bivirkninger direkte til L√¶gemiddelstyrelsen via de oplysninger der fremg√•r herunder. Ved at indrapportere bivirkninger kan du hj√¶lpe med at fremskaffe mere information om sikkerheden af dette l√¶gemiddel.</div>
                        <div class="paragraph">
                           <br/>L√¶gemiddelstyrelsen </div>
                        <div class="paragraph">Axel Heides Gade 1 </div>
                        <div class="paragraph">DK-2300 K√∏benhavn S</div>
                        <div class="paragraph">Websted: www.meldenbivirkning.dk</div>
                        <div class="paragraph">
                           <a href="https://www.meldenbivirkning.dk" title="Meld en bivirkning">
								Meld en bivirkning.
							</a>
                        </div>
                     </div>
            </text>
          </section>
          <section>
            <title value="5. Opbevaring"/>
            <code>
              <coding>
                <system value="https://spor.ema.europa.eu/v1/lists/200000029659/terms/"/>
                <code value="200000029913"/>
              </coding>
            </code>
            <text>
              <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                        <a name="Section5"/>
                        <div>¬†</div>
                        <h2>5. Opbevaring</h2>
                        <div class="paragraph">Opbevar l√¶gemidlet utilg√¶ngeligt for b√∏rn.</div>
                        <div class="paragraph">
                           <br/>Brug ikke l√¶gemidlet efter den udl√∏bsdato, der st√•r p√• etiketten/blisterpakningen/pakningen efter EXP. Udl√∏bsdatoen er den sidste dag i den n√¶vnte m√•ned.</div>
                        <div class="paragraph">
                           <br/>Opbevares i k√∏leskab (2 - 8¬∞C). M√• ikke nedfryses. </div>
                        <div class="paragraph">
                           <br/>Opbevar den fyldte pen i den ydre karton for at beskytte mod lys.</div>
                        <div class="paragraph">
                           <br/>
                           <b>Alternativ opbevaring:</b>
                        </div>
                        <div class="paragraph">Hvis det er n√∏dvendigt (f.eks. n√•r du rejser), kan Hyrimoz opbevares ved stuetemperatur (op til 25¬∞C) i en periode p√• h√∏jst 21 dage - s√∏rg for at beskytte det mod lys. N√•r din fyldte pen er taget ud af k√∏leskabet og opbevaret ved stuetemperatur, <b>skal pennen bruges indenfor 21 dage eller kasseres</b>, ogs√• selv om den senere l√¶gges tilbage i k√∏leskabet. Du skal registrere den dato, hvor din fyldte pen f√∏rst tages ud af k√∏leskabet, og den dato efter hvilken, den skal kasseres.</div>
                        <div class="paragraph">
                           <br/>Sp√∏rg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til milj√∏et m√• du ikke smide medicinrester i afl√∏bet, toilettet eller skraldespanden.</div>
                     </div>
            </text>
          </section>
          <section>
            <title value="6. Pakningsst√∏rrelser og yderligere oplysninger"/>
            <code>
              <coding>
                <system value="https://spor.ema.europa.eu/v1/lists/200000029659/terms/"/>
                <code value="200000029914"/>
              </coding>
            </code>
            <text>
              <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                        <a name="Section6"/>
                        <div>¬†</div>
                        <h2>6. Pakningsst√∏rrelser og yderligere oplysninger</h2>
                        <h3>  Hyrimoz indeholder  </h3>
                        <ul>
                           <li>Aktivt stof: adalimumab. Hver fyldt pen indeholder 40 mg adalimumab i 0,8 ml opl√∏sning. </li>
                           <li>√òvrige indholdsstoffer: adipinsyre, citronsyremonohydrat, natriumchlorid, mannitol, polysorbat 80, saltsyre, natriumhydroxid og vand til injektionsv√¶sker. </li>
                        </ul>
                        <h3>  Udseende og pakningsst√∏rrelser  </h3>
                        <div class="paragraph">Hyrimoz 40 mg injektionsv√¶ske, opl√∏sning (injektion) i fyldt pen leveres som en 0,8 ml klar til lettere opaliserende, farvel√∏s til let gullig injektionsv√¶ske.</div>
                        <div class="paragraph">
                           <br/>Hyrimoz leveres i en fyldt engangsspr√∏jte samlet til en trekantformet pen med transparent vindue og etiket (SensoReady pen). Spr√∏jten inden i pennen er lavet af type I-glas med en kanyle i rustfrit st√•l og en indre kanyleh√¶tte i gummi indeholdende 0,8 ml injektionsv√¶ske.</div>
                        <div class="paragraph">
                           <br/>Pakningerne indeholder 1 og 2 fyldte penne med Hyrimoz.<br/>Multipakninger indeholder 6 (3 pakninger a 2) fyldte penne med Hyrimoz.</div>
                        <div class="paragraph">
                           <br/>Ikke alle pakningsst√∏rrelser er n√∏dvendigvis markedsf√∏rt.<br/>Hyrimoz findes som en fyldt injektionsspr√∏jte og en fyldt pen (SensoReady).</div>
                     </div>
            </text>
            <section>
              <title value="Indehaver af markedsf√∏ringstilladelsen og fremstiller"/>
              <code>
                <coding>
                  <system value="https://spor.ema.europa.eu/v1/lists/200000029659/terms/"/>
                  <code value="200000029917"/>
                </coding>
              </code>
              <text>
                <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                           <h2>Indehaver af markedsf√∏ringstilladelsen og fremstiller</h2>
                           <h3>  Indehaver af markedsf√∏ringstilladelsen  </h3>
                           <div class="paragraph">Sandoz GmbH</div>
                           <div class="paragraph">Biochemiestr. 10</div>
                           <div class="paragraph">6250 Kundl</div>
                           <div class="paragraph">√òstrig</div>
                           <h3>  Fremstiller  </h3>
                           <div class="paragraph">Sandoz GmbH Schaftenau</div>
                           <div class="paragraph">Biochemiestr. 10</div>
                           <div class="paragraph">6336 Langkampfen</div>
                           <div class="paragraph">√òstrig<br/>
                              <br/>Hvis du √∏nsker yderligere oplysninger om dette l√¶gemiddel, skal du henvende dig til den lokale repr√¶sentant for indehaveren af markedsf√∏ringstilladelsen: <br/>
                              <br/>
                              <b>Sandoz A/S </b>
                              <br/>Tlf: +45 63 95 10 00</div>
                           <h3>  Andre informationskilder  </h3>
                           <div class="paragraph">Du kan finde yderligere oplysninger om dette l√¶gemiddel p√• Det Europ√¶iske L√¶gemiddelagenturs hjemmeside: http://www.ema.europa.eu.</div>
                        </div>
              </text>
            </section>
            <section>
              <title value="Denne indl√¶gsseddel blev senest √¶ndret 06/2021"/>
              <code>
                <coding>
                  <system value="https://spor.ema.europa.eu/v1/lists/200000029659/terms/"/>
                  <code value="200000029919"/>
                </coding>
              </code>
              <text>
                <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                           <h2>Denne indl√¶gsseddel blev senest √¶ndret 06/2021</h2>
                        </div>
              </text>
            </section>
            <section>
              <title value="7. 7. Brugsvejledning"/>
              <code>
                <coding>
                  <system value="https://spor.ema.europa.eu/v1/lists/200000029659/terms/"/>
                  <code value="200000029920"/>
                </coding>
              </code>
              <text>
                <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                           <a name="Section8"/>
                           <div>¬†</div>
                           <h2>7. 7. Brugsvejledning</h2>
                           <div class="paragraph">For at undg√• infektioner og for at sikre, at du bruger medicinen korrekt, er det vigtigt, at du f√∏lger denne vejledning.</div>
                           <div class="paragraph">
                              <br/>S√∏rg for at l√¶se, forst√• og f√∏lge denne brugsvejledning, f√∏r du injicerer Hyrimoz. Din l√¶ge viser dig, hvordan du skal forberede og injicere Hyrimoz korrekt med den fyldte pen, inden du bruger det for f√∏rste gang. Tal med din l√¶ge, hvis du har nogen sp√∏rgsm√•l.<br/>
                              <br/>
                              <b>Din Hyrimoz fyldte SensoReady pen til engangsbrug</b>
                           </div>
                           <div class="paragraph">
                              <img src="#175114" alt="Hyrimoz Sandoz GmbH injektionsv√¶ske, opl√∏sning i fyldt pen 40 mg"/>
                           </div>
                           <div class="paragraph">¬†</div>
                           <div class="paragraph">I <b>Figur A </b>er pennen vist med h√¶tten fjernet. Fjern ikke h√¶tten, f√∏r du er klar til at injicere.</div>
                           <h3>  Det er vigtigt, at du:  </h3>
                           <ul>
                              <li>
                                 <b>ikke √•bner </b>den ydre emballage, f√∏r du er klar til at bruge pennen </li>
                              <li>
                                 <b>ikke bruger </b>pennen, hvis enten forseglingen p√• den ydre emballage eller sikkerhedsforseglingen p√• pennen er itu. </li>
                              <li>
                                 <b>aldrig efterlader </b>pennen uden opsyn, hvor andre kan komme i kontakt med den. </li>
                              <li>hvis du taber pennen, s√• <b>brug den ikke</b>, hvis den ser ud til at v√¶re beskadiget, eller hvis du tabte den, uden at h√¶tten var p√•. </li>
                              <li>injicer Hyrimoz 15-30 minutter efter, at du har taget det ud af k√∏leskabet for at f√• en mere behagelig injektion. </li>
                              <li>smid den brugte pen bort, straks efter at du har brugt den. <b>Brug ikke pennen igen</b>. Se &quot;<b>8. Bortskaffelse af brugte penne</b>&quot; i slutningen af denne brugsvejledning. </li>
                           </ul>
                           <h3>  S√•dan skal du opbevare din pen:  </h3>
                           <ul>
                              <li>Opbevar din pen i pakningen i et k√∏leskab, mellem 2 ¬∞C og 8 ¬∞C. </li>
                              <li>Hvis det er n√∏dvendigt (f.eks. n√•r du rejser), kan Hyrimoz opbevares ved stuetemperatur (op til 25 ¬∞C) i en periode p√• h√∏jst 21 dage - s√∏rg for at beskytte den mod lys. N√•r pennen er taget ud af k√∏leskabet og har v√¶ret opbevaret ved stuetemperatur, skal pennen <b>bruges indenfor 21 dage eller kasseres</b>, ogs√• selv om den senere l√¶gges tilbage i k√∏leskabet. Du skal registrere den dato, hvor pennen f√∏rst tages ud af k√∏leskabet, og den dato efter hvilken, den skal kasseres. </li>
                              <li>Opbevar din pen i den originale pakning, indtil du er klar til at bruge dem, for at beskytte dem mod lys. </li>
                              <li>Opbevar ikke din pen i ekstrem varme eller kulde. </li>
                              <li>Din pen m√• ikke nedfryses. </li>
                           </ul>
                           <div class="paragraph">
                              <br/>
                              <b>Hyrimoz og andre l√¶gemidler skal opbevares uden for b√∏rns r√¶kkevidde.</b>
                           </div>
                           <h3>  Hvad skal du bruge til din injektion?  </h3>
                           <div class="paragraph">L√¶g f√∏lgende ting p√• et rent og fladt underlag.</div>
                           <div class="paragraph">
                              <br/>I din pakning finder du:</div>
                           <ul>
                              <li>Hyrimoz fyldt(e) Senso-Ready pen(ne) (se <b>Figur A</b>). Hver pen indeholder 40 mg/0,8 ml Hyrimoz. </li>
                           </ul>
                           <div class="paragraph">
                              <br/>F√∏lgende er ikke inkluderet i din pakning (se <b>Figur B</b>):</div>
                           <ul>
                              <li>Alkoholserviet </li>
                              <li>Bomuldsvatkugle eller gazebind </li>
                              <li>Kanyleboks </li>
                           </ul>
                           <div class="paragraph">¬†</div>
                           <div class="paragraph">
                              <img src="#175115" alt="Hyrimoz Sandoz GmbH injektionsv√¶ske, opl√∏sning i fyldt pen 40 mg"/>
                           </div>
                           <div class="paragraph">¬†</div>
                           <div class="paragraph">Se &quot;<b>8. Bortskaffelse af brugte penne</b>&quot; i slutningen af denne brugsvejledning.</div>
                           <h3>  F√∏r injektion  </h3>
                           <div class="paragraph">
                              <b>Forberedelse af pennen</b>
                           </div>
                           <ul>
                              <li>For at f√• en mere behagelig injektion, kan du tage Hyrimoz ud af k√∏leskabet 15-30 minutter f√∏r, du injicerer det, s√• det kan n√• at f√• stuetemperatur. </li>
                              <li>Se godt efter i vinduet. Opl√∏sningen skal v√¶re farvel√∏s til let gullig og klar til let opaliserende. <b>Brug den ikke</b>, hvis du ser partikler og/eller misfarvning. Hvis du er bekymret over, hvordan opl√∏sningen ser ud, s√• kontakt apotekspersonalet for at f√• hj√¶lp.<br/>
                                 <img src="#175116" alt="Hyrimoz Sandoz GmbH injektionsv√¶ske, opl√∏sning i fyldt pen 40 mg"/>
                              </li>
                              <li>Kontroller udl√∏bsdatoen (EXP) p√• din pen. Brug den ikke efter den angivne udl√∏bsdato. </li>
                              <li>Brug den ikke, hvis sikkerhedsforseglingen er brudt. </li>
                           </ul>
                           <div class="paragraph">
                              <br/>
                              <b>Kontakt dit apotekspersonale, hvis pennen ikke kan klare alle ovenst√•ende tjek.</b>
                           </div>
                           <div class="paragraph">¬†</div>
                           <div class="paragraph">
                              <b>1. Valg af injektionsstedet: </b>
                           </div>
                           <ul>
                              <li>Anbefalet injektionssted er p√• forsiden af dine l√•r. Du kan ogs√• bruge nederste del af maven men ikke i et omr√•de i en omkreds p√• 5 cm rundt om din navle (se <b>Figur D</b>).<br/>
                                 <img src="#175117" alt="Hyrimoz Sandoz GmbH injektionsv√¶ske, opl√∏sning i fyldt pen 40 mg"/>
                              </li>
                              <li>V√¶lg et andet omr√•de, hver gang du giver dig selv en injektion. </li>
                              <li>Injicer ikke i et omr√•de, hvor huden er √∏m, har bl√• m√¶rker, er r√∏d, sk√¶ller eller er h√•rd. Undg√• omr√•der med ar eller str√¶km√¶rker. Hvis du har psoriasis, skal du IKKE injicere direkte i omr√•der med plaque-psoriasis. </li>
                           </ul>
                           <div class="paragraph">¬†</div>
                           <div class="paragraph">
                              <b>2. Rensning af injektionsstedet: </b>
                           </div>
                           <ul>
                              <li>Vask dine h√¶nder grundigt med s√¶be og vand. </li>
                              <li>Rens injektionsstedet med en alkoholserviet ved hj√¶lp af cirklende bev√¶gelser. Lad det t√∏rre, f√∏r du injicerer (se <b>Figur E</b>).<br/>
                                 <img src="#175118" alt="Hyrimoz Sandoz GmbH injektionsv√¶ske, opl√∏sning i fyldt pen 40 mg"/>
                              </li>
                              <li>R√∏r ikke ved det rensede omr√•de, f√∏r du injicerer. </li>
                           </ul>
                           <div class="paragraph">¬†</div>
                           <div class="paragraph">
                              <b>3. Aftagning af pennens h√¶tte: </b>
                           </div>
                           <ul>
                              <li>Fjern f√∏rst h√¶tten, n√•r du er klat til at bruge pennen. </li>
                              <li>Drej h√¶tten af i pilenes retning (se <b>Figur F</b>).<br/>
                                 <img src="#175119" alt="Hyrimoz Sandoz GmbH injektionsv√¶ske, opl√∏sning i fyldt pen 40 mg"/>
                              </li>
                              <li>N√•r h√¶tten er fjernet, s√• smid den bort. <b>Pr√∏v ikke at s√¶tte h√¶tten p√• igen</b>. </li>
                              <li>Brug pennen inden for 5 minutter efter, at du har fjernet h√¶tten. </li>
                              <li>M√•ske ser du et par dr√•ber v√¶ske komme ud af kanylen. Det er normalt. </li>
                           </ul>
                           <div class="paragraph">¬†</div>
                           <div class="paragraph">
                              <b>4. S√•dan holdes pennen: </b>
                           </div>
                           <ul>
                              <li>Hold din pen i en vinkel p√• 90¬∞ mod det rensede injektionssted (se <b>Figur G</b>).<br/>
                                 <img src="#175121" alt="Hyrimoz Sandoz GmbH injektionsv√¶ske, opl√∏sning i fyldt pen 40 mg"/>
                                 <br/>
                                 <img src="#175120" alt="Hyrimoz Sandoz GmbH injektionsv√¶ske, opl√∏sning i fyldt pen 40 mg"/>
                              </li>
                           </ul>
                           <h3>  Din injektion  </h3>
                           <div class="paragraph">¬†</div>
                           <div class="paragraph">
                              <b>L√¶s dette, f√∏r du injicerer</b>
                           </div>
                           <div class="paragraph">
                              <br/>Mens du injicerer, vil du h√∏re <b>2 h√∏je klik</b>:</div>
                           <ul>
                              <li>Det <b>f√∏rste klik </b>betyder, at injektionen er <b>begyndt</b>. </li>
                              <li>Flere sekunder senere vil det <b>andet klik </b>betyde, at injektionen <b>n√¶sten </b>er f√¶rdig. </li>
                           </ul>
                           <div class="paragraph">
                              <br/>Du skal holde pennen fast mod huden, indtil du ser en <b>gr√∏n indikator </b>fylde vinduet og holde op med at bev√¶ge sig.</div>
                           <div class="paragraph">¬†</div>
                           <div class="paragraph">
                              <b>5. P√•begynd din injektion: </b>
                           </div>
                           <ul>
                              <li>Tryk din pen fast mod huden for at p√•begynde injektionen (se <b>Figur H</b>).<br/>
                                 <img src="#175122" alt="Hyrimoz Sandoz GmbH injektionsv√¶ske, opl√∏sning i fyldt pen 40 mg"/>
                              </li>
                              <li>Det <b>f√∏rste klik </b>betyder, at injektionen er begyndt. </li>
                              <li>
                                 <b>Bliv ved med at holde </b>pennen fast mod huden. </li>
                              <li>Den gr√∏nne indikator viser, hvordan injektionen skrider frem. </li>
                           </ul>
                           <div class="paragraph">¬†</div>
                           <div class="paragraph">
                              <b>6. Afslut din injektion: </b>
                           </div>
                           <ul>
                              <li>Lyt efter det <b>andet klik</b>. Det indikerer, at injektionen <b>n√¶sten </b>er f√¶rdig. </li>
                              <li>Kontroller, at den gr√∏nne indikator fylder vinduet og er holdt op med at bev√¶ge sig (se <b>Figur I</b>).<br/>
                                 <img src="#175123" alt="Hyrimoz Sandoz GmbH injektionsv√¶ske, opl√∏sning i fyldt pen 40 mg"/>
                              </li>
                              <li>Pennen kan nu fjernes. </li>
                           </ul>
                           <h3>  Efter din injektion  </h3>
                           <div class="paragraph">
                              <b>7. Kontroller, at den gr√∏nne indikator fylder vinduet (se Figur J): </b>
                           </div>
                           <div class="paragraph">
                              <img src="#175124" alt="Hyrimoz Sandoz GmbH injektionsv√¶ske, opl√∏sning i fyldt pen 40 mg"/>
                           </div>
                           <ul>
                              <li>Det betyder, at medicinen er indgivet. Kontakt din l√¶ge, hvis du ikke kan se den gr√∏nne indikator. </li>
                              <li>Der kan v√¶re en lille smule blod p√• injektionsstedet. Du kan presse en vatkugle eller et gazebind p√• injektionsstedet og holde det fast i 10 sekunder. Gnid ikke p√• injektionsstedet. Du kan d√¶kke injektionsstedet med et lille plaster, hvis det er n√∏dvendigt. </li>
                           </ul>
                           <div class="paragraph">¬†</div>
                           <div class="paragraph">
                              <b>8. Bortskaffelse af brugte penne: </b>
                           </div>
                           <ul>
                              <li>De brugte penne bortskaffes i en kanyleboks (lukkelig, brudfast beholder). Pennene m√• aldrig genbruges af hensyn til sikkerheden for dig og andre.<br/>
                                 <img src="#175125" alt="Hyrimoz Sandoz GmbH injektionsv√¶ske, opl√∏sning i fyldt pen 40 mg"/>
                              </li>
                              <li>Sp√∏rg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til milj√∏et m√• du ikke smide medicinrester i afl√∏bet, toilettet eller skraldespanden. </li>
                           </ul>
                           <div class="paragraph">¬†</div>
                           <div class="paragraph">
                              <b>Hvis du har nogen sp√∏rgsm√•l, s√• tal med en l√¶ge, apotekspersonalet eller en sygeplejerske, som kender Hyrimoz.</b>
                           </div>
                        </div>
              </text>
              <entry>
                <reference value="#175114"/>
              </entry>
              <entry>
                <reference value="#175115"/>
              </entry>
              <entry>
                <reference value="#175116"/>
              </entry>
              <entry>
                <reference value="#175117"/>
              </entry>
              <entry>
                <reference value="#175118"/>
              </entry>
              <entry>
                <reference value="#175119"/>
              </entry>
              <entry>
                <reference value="#175121"/>
              </entry>
              <entry>
                <reference value="#175120"/>
              </entry>
              <entry>
                <reference value="#175122"/>
              </entry>
              <entry>
                <reference value="#175123"/>
              </entry>
              <entry>
                <reference value="#175124"/>
              </entry>
              <entry>
                <reference value="#175125"/>
              </entry>
            </section>
          </section>
        </section>
      </Composition>
    </resource>
  </entry>
  <entry>
    <fullUrl value="https://gravitatehealth.eu/fhir/nordic-epi/MedicinalProductDefinition/IBD-MPD-2"/>
    <resource>
      <MedicinalProductDefinition>
        <id value="IBD-MPD-2"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
          <profile value="https://gravitatehealth.eu/fhir/nordic-epi-ig/StructureDefinition/Nordic-ePI-MedicinalProductDefinition"/>
        </meta>
        <text>
          <status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_IBD-MPD-2"> </a><p><b>Generated Narrative: MedicinalProductDefinition</b><a name="IBD-MPD-2"> </a><a name="hcIBD-MPD-2"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Resource MedicinalProductDefinition &quot;IBD-MPD-2&quot; </p><p style="margin-bottom: 0px">Profiles: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info//StructureDefinition-MedicinalProductDefinition-uv-epi.html">MedicinalProductDefinition (ePI)</a>, <code>https://gravitatehealth.eu/fhir/nordic-epi-ig/StructureDefinition/Nordic-ePI-MedicinalProductDefinition</code></p></div><p><b>identifier</b>: <code>http://legemiddelverket.no/FEST/LegemiddelMerkevareID</code>/ID_1664C6BC-1486-4845-84F2-E3449D87C8CF</p><h3>Names</h3><table class="grid"><tr><td style="display: none">-</td><td><b>ProductName</b></td></tr><tr><td style="display: none">*</td><td>Hyrimoz inj, oppl 40 mg/penn</td></tr></table></div>
        </text>
        <identifier>
          <system value="http://legemiddelverket.no/FEST/LegemiddelMerkevareID"/>
          <value value="ID_1664C6BC-1486-4845-84F2-E3449D87C8CF"/>
        </identifier>
        <name>
          <productName value="Hyrimoz inj, oppl 40 mg/penn"/>
        </name>
      </MedicinalProductDefinition>
    </resource>
  </entry>
  <entry>
    <fullUrl value="https://gravitatehealth.eu/fhir/nordic-epi/PackagedProductDefinition/IBD-PPD-2"/>
    <resource>
      <PackagedProductDefinition>
        <id value="IBD-PPD-2"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/PackagedProductDefinition-uv-epi"/>
          <profile value="https://gravitatehealth.eu/fhir/nordic-epi-ig/StructureDefinition/Nordic-ePI-PackagedProductDefinition"/>
        </meta>
        <text>
          <status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml"><a name="PackagedProductDefinition_IBD-PPD-2"> </a><p><b>Generated Narrative: PackagedProductDefinition</b><a name="IBD-PPD-2"> </a><a name="hcIBD-PPD-2"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Resource PackagedProductDefinition &quot;IBD-PPD-2&quot; </p><p style="margin-bottom: 0px">Profiles: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info//StructureDefinition-PackagedProductDefinition-uv-epi.html">PackagedProductDefinition (ePI)</a>, <code>https://gravitatehealth.eu/fhir/nordic-epi-ig/StructureDefinition/Nordic-ePI-PackagedProductDefinition</code></p></div><p><b>identifier</b>: <code>http://legemiddelverket.no/FEST/LegemiddelPakningID</code>/ID_2435E692-0ED8-4423-8B8C-9E8676D1C7CA, <code>https://farmalogg.no/varenummer</code>/159199, <code>https://pharmaca.fi/vnr</code>/371157</p><p><b>name</b>: Hyrimoz inj, oppl 40 mg/penn</p><p><b>packageFor</b>: <a href="#MedicinalProductDefinition_IBD-MPD-2">See above (MedicinalProductDefinition/IBD-MPD-2)</a></p></div>
        </text>
        <identifier>
          <system value="http://legemiddelverket.no/FEST/LegemiddelPakningID"/>
          <value value="ID_2435E692-0ED8-4423-8B8C-9E8676D1C7CA"/>
        </identifier>
        <identifier>
          <system value="https://farmalogg.no/varenummer"/>
          <value value="159199"/>
        </identifier>
        <identifier>
          <system value="https://pharmaca.fi/vnr"/>
          <value value="371157"/>
        </identifier>
        <name value="Hyrimoz inj, oppl 40 mg/penn"/>
        <packageFor>
          <reference value="MedicinalProductDefinition/IBD-MPD-2"/>
        </packageFor>
      </PackagedProductDefinition>
    </resource>
  </entry>
</Bundle>